DoubleClick的个人主页 - 老虎社区

DoubleClick

DoubleClick

暂无个人介绍

IP属地：未知

19关注

5粉丝

0主题

0勋章

2021-11-25

$iQiyi Inc.(IQ)$ 是我的第一次

@小虎活动:【感恩回馈】说说你和老虎的第一次

2021-11-25

小米就是要放长线钓大鱼！$XIAOMI-W(01810)$

@话题虎:小米净利润大长25.4%！为什么又跌了？何时能抄底？

2021-11-25

我的计划是等着看

@Buy_Sell:🚀【11月24日】涨跌不一，油价上演大逆转！今天什么值得买

2021-11-23

[Cool]

抱歉，原内容已删除

2021-11-21

$Apple(AAPL)$Ride the upward momentum!

2021-11-17

$iQiyi Inc.(IQ)$For long term play? 💎✊🏻

2021-11-15

Here for the coins!

@期权异动观察:11.15期权异动观察，AMD反复异动

2021-11-11

Lol need more words in the thesaurus for “drop”.

Continued Consolidation Called For Singapore Shares<blockquote>新加坡股市需要持续整合</blockquote>

2021-11-04

Happy Diwali Everyone!

2021-11-01

Nice!

2 Growth Stocks That Could Deliver 1,000% Returns<blockquote>2只可带来1,000%回报的成长型股票</blockquote>

2021-06-20

Latest

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3574933488250733","uuid":"3574933488250733","gmtCreate":1611839465354,"gmtModify":1635779542349,"name":"DoubleClick","pinyin":"doubleclick","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/91c1a51c4f84aa921e0b29d4e1b8f7e1","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":5,"headSize":19,"tweetSize":11,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.09.26","exceedPercentage":"60.86%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.06.15","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.03.23","exceedPercentage":"60.77%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":874477757,"gmtCreate":1637818653179,"gmtModify":1637818653328,"author":{"id":"3574933488250733","authorId":"3574933488250733","name":"DoubleClick","avatar":"https://static.tigerbbs.com/91c1a51c4f84aa921e0b29d4e1b8f7e1","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574933488250733","idStr":"3574933488250733"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/IQ\">$iQiyi Inc.(IQ)$</a> 是我的第一次","listText":"<a href=\"https://laohu8.com/S/IQ\">$iQiyi Inc.(IQ)$</a> 是我的第一次","text":"$iQiyi Inc.(IQ)$ 是我的第一次","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/874477757","repostId":"875266611","repostType":1,"repost":{"id":875266611,"gmtCreate":1637659026330,"gmtModify":1637929617182,"author":{"id":"36984908995200","authorId":"36984908995200","name":"小虎活动","avatar":"https://static.tigerbbs.com/9e396d03155923b283948d2dec9191f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"36984908995200","idStr":"36984908995200"},"themes":[],"title":"【感恩回馈】说说你和老虎的第一次","htmlText":"感恩节马上要到了，小虎提醒：感恩节周四(11月25日)美股休市哦！感恩节翌日(26日)美股提前3小时收盘~ 为了回馈广大虎友们的支持与陪伴，小虎君为大家准备了一些小礼物，参与即可获赠66虎币，如果你愿意多聊2句，还有机会获得小虎全套盲盒。 不知不觉，老虎已经成立7年了， 在过去年的7年，我们认识了很多新老朋友 可曾记得你是何时加入老虎的？ 又是缘何来到这里？ 【参与方式】 本帖留言说出 「你和老虎的第一次」 你发布的第一个帖子是什么？ 你关注的第一个好友是谁？ 你关注/交易的第一只股票是什么？ 【活动奖励】 凡是参与晒单的虎友均可获得66虎币，除此之外，还有机会获得以下奖励： 知己奖：我们会选取“第一条帖子”发帖时间最早的虎友赠予1套小虎盲盒手办（5个） 人气奖：我们会选取评论获赞量最高的3位虎友，随机赠予小虎盲盒手办1个 优质奖：我们会随机选取评论优质有趣的虎友，随机赠予小虎盲盒手办1个 【活动时间】： 2021年11月23日-11月29日 【特别说明】 水贴，重复内容，广告，恶意营销等属于无效内容； 文章需原创并首发于老虎，并且版权归老虎社区所有； 本次活动中用户所提到的标的，仅供参考，不构成投资建议，据此操作，风险自负； 活动最终解释权归老虎社区所有； 若对本次活动有不解之处，可在此贴留言，或微信虎妞（微信号：itiger2014）咨询。 欢迎大家在下贴评论区留言说说「你和老虎的第一次」，你发布的第一个帖子是什么？你关注的第一个好友是谁？你关注/交易的第一只股票是什么？参与即可获赠66虎币，如果你愿意多聊2句，还有机会获得小虎全套盲盒。","listText":"感恩节马上要到了，小虎提醒：感恩节周四(11月25日)美股休市哦！感恩节翌日(26日)美股提前3小时收盘~ 为了回馈广大虎友们的支持与陪伴，小虎君为大家准备了一些小礼物，参与即可获赠66虎币，如果你愿意多聊2句，还有机会获得小虎全套盲盒。 不知不觉，老虎已经成立7年了， 在过去年的7年，我们认识了很多新老朋友 可曾记得你是何时加入老虎的？ 又是缘何来到这里？ 【参与方式】 本帖留言说出 「你和老虎的第一次」 你发布的第一个帖子是什么？ 你关注的第一个好友是谁？ 你关注/交易的第一只股票是什么？ 【活动奖励】 凡是参与晒单的虎友均可获得66虎币，除此之外，还有机会获得以下奖励： 知己奖：我们会选取“第一条帖子”发帖时间最早的虎友赠予1套小虎盲盒手办（5个） 人气奖：我们会选取评论获赞量最高的3位虎友，随机赠予小虎盲盒手办1个 优质奖：我们会随机选取评论优质有趣的虎友，随机赠予小虎盲盒手办1个 【活动时间】： 2021年11月23日-11月29日 【特别说明】 水贴，重复内容，广告，恶意营销等属于无效内容； 文章需原创并首发于老虎，并且版权归老虎社区所有； 本次活动中用户所提到的标的，仅供参考，不构成投资建议，据此操作，风险自负； 活动最终解释权归老虎社区所有； 若对本次活动有不解之处，可在此贴留言，或微信虎妞（微信号：itiger2014）咨询。 欢迎大家在下贴评论区留言说说「你和老虎的第一次」，你发布的第一个帖子是什么？你关注的第一个好友是谁？你关注/交易的第一只股票是什么？参与即可获赠66虎币，如果你愿意多聊2句，还有机会获得小虎全套盲盒。","text":"感恩节马上要到了，小虎提醒：感恩节周四(11月25日)美股休市哦！感恩节翌日(26日)美股提前3小时收盘~ 为了回馈广大虎友们的支持与陪伴，小虎君为大家准备了一些小礼物，参与即可获赠66虎币，如果你愿意多聊2句，还有机会获得小虎全套盲盒。 不知不觉，老虎已经成立7年了， 在过去年的7年，我们认识了很多新老朋友 可曾记得你是何时加入老虎的？ 又是缘何来到这里？ 【参与方式】 本帖留言说出 「你和老虎的第一次」 你发布的第一个帖子是什么？ 你关注的第一个好友是谁？ 你关注/交易的第一只股票是什么？ 【活动奖励】 凡是参与晒单的虎友均可获得66虎币，除此之外，还有机会获得以下奖励： 知己奖：我们会选取“第一条帖子”发帖时间最早的虎友赠予1套小虎盲盒手办（5个） 人气奖：我们会选取评论获赞量最高的3位虎友，随机赠予小虎盲盒手办1个 优质奖：我们会随机选取评论优质有趣的虎友，随机赠予小虎盲盒手办1个 【活动时间】： 2021年11月23日-11月29日 【特别说明】 水贴，重复内容，广告，恶意营销等属于无效内容； 文章需原创并首发于老虎，并且版权归老虎社区所有； 本次活动中用户所提到的标的，仅供参考，不构成投资建议，据此操作，风险自负； 活动最终解释权归老虎社区所有； 若对本次活动有不解之处，可在此贴留言，或微信虎妞（微信号：itiger2014）咨询。 欢迎大家在下贴评论区留言说说「你和老虎的第一次」，你发布的第一个帖子是什么？你关注的第一个好友是谁？你关注/交易的第一只股票是什么？参与即可获赠66虎币，如果你愿意多聊2句，还有机会获得小虎全套盲盒。","images":[{"img":"https://static.tigerbbs.com/b56d1364489aaafc34e363d2b2b842a8","width":"1462","height":"818"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875266611","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":2288,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":874434632,"gmtCreate":1637809697526,"gmtModify":1637809697589,"author":{"id":"3574933488250733","authorId":"3574933488250733","name":"DoubleClick","avatar":"https://static.tigerbbs.com/91c1a51c4f84aa921e0b29d4e1b8f7e1","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574933488250733","idStr":"3574933488250733"},"themes":[],"htmlText":"小米就是要放长线钓大鱼！<a href=\"https://laohu8.com/S/01810\">$XIAOMI-W(01810)$</a>","listText":"小米就是要放长线钓大鱼！<a href=\"https://laohu8.com/S/01810\">$XIAOMI-W(01810)$</a>","text":"小米就是要放长线钓大鱼！$XIAOMI-W(01810)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/874434632","repostId":"874394828","repostType":1,"repost":{"id":874394828,"gmtCreate":1637727980561,"gmtModify":1637730601856,"author":{"id":"3502767768442965","authorId":"3502767768442965","name":"话题虎","avatar":"https://static.tigerbbs.com/d418c2def5dc1d094b03270b450f71ce","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3502767768442965","idStr":"3502767768442965"},"themes":[],"title":"小米净利润大长25.4%！为什么又跌了？何时能抄底？","htmlText":" 昨天，小米发布Q3财报： 营收781亿元，同比增长8.2%；净利润52亿元，同比增长25.4%。 分业务来看： 智能手机： 三季度收入478亿元。 手机销售单价同比增长6.7%，达到1,090.5元，整体毛利率同比增长4.4个百分点，达到12.8%； 本季度智能手机出货量4,390万部，排名世界第三，前三季出货量与去年全年相当； 高端旗舰手机出货量近1800万台，占比超12%。 IoT与生活消费产品： 三季度收入209亿元，同比增长15.5%； 平板、智能电视、空调出货量持续增加； 在可穿戴产品，第三季度全球市场份额排名第二。 互联网服务业务： 三季度收入73亿元，同比增长27.1%，创历史新高； 毛利率73.6%，同比提升13.1个百分点； 广告收入48亿元，同比增长44.7%； 游戏收入10亿元，同比增长25.0%。 从地区上看，三季度： 境外收入，占比高达52.4%； 小米手机在全球11个国家和地区市占率排名第一，在全球59个国家和地区市占率排名前五；在印度市场连续第16个季度保持出货量第一。 智能电动汽车和其他业务： 团队成员已超过500人，预计2024年上半年正式量产； AIoT平台已连接的IoT设备（不包括智能手机、平板及笔记本计算机）数首次突破4&nbsp;亿，同比增长33.1%； 小米在中国大陆的零售店总数已突破10,000家。 小话感觉小米又交出了一份非常ok的财报，可是为啥股价大跌呢？ 想不通。 …… 最后，大家聊一聊： 你认为小米的财报ok吗？小米跌到什么时候能抄底？ 精彩留言用户可获得888社区积分噢！ <a target=\"_blank\" href=\"https://laohu8.com/S/01810\">$小米集团-W(01810)$</a>","listText":" 昨天，小米发布Q3财报： 营收781亿元，同比增长8.2%；净利润52亿元，同比增长25.4%。 分业务来看： 智能手机： 三季度收入478亿元。 手机销售单价同比增长6.7%，达到1,090.5元，整体毛利率同比增长4.4个百分点，达到12.8%； 本季度智能手机出货量4,390万部，排名世界第三，前三季出货量与去年全年相当； 高端旗舰手机出货量近1800万台，占比超12%。 IoT与生活消费产品： 三季度收入209亿元，同比增长15.5%； 平板、智能电视、空调出货量持续增加； 在可穿戴产品，第三季度全球市场份额排名第二。 互联网服务业务： 三季度收入73亿元，同比增长27.1%，创历史新高； 毛利率73.6%，同比提升13.1个百分点； 广告收入48亿元，同比增长44.7%； 游戏收入10亿元，同比增长25.0%。 从地区上看，三季度： 境外收入，占比高达52.4%； 小米手机在全球11个国家和地区市占率排名第一，在全球59个国家和地区市占率排名前五；在印度市场连续第16个季度保持出货量第一。 智能电动汽车和其他业务： 团队成员已超过500人，预计2024年上半年正式量产； AIoT平台已连接的IoT设备（不包括智能手机、平板及笔记本计算机）数首次突破4&nbsp;亿，同比增长33.1%； 小米在中国大陆的零售店总数已突破10,000家。 小话感觉小米又交出了一份非常ok的财报，可是为啥股价大跌呢？ 想不通。 …… 最后，大家聊一聊： 你认为小米的财报ok吗？小米跌到什么时候能抄底？ 精彩留言用户可获得888社区积分噢！ <a target=\"_blank\" href=\"https://laohu8.com/S/01810\">$小米集团-W(01810)$</a>","text":"昨天，小米发布Q3财报： 营收781亿元，同比增长8.2%；净利润52亿元，同比增长25.4%。 分业务来看： 智能手机： 三季度收入478亿元。 手机销售单价同比增长6.7%，达到1,090.5元，整体毛利率同比增长4.4个百分点，达到12.8%； 本季度智能手机出货量4,390万部，排名世界第三，前三季出货量与去年全年相当； 高端旗舰手机出货量近1800万台，占比超12%。 IoT与生活消费产品： 三季度收入209亿元，同比增长15.5%； 平板、智能电视、空调出货量持续增加； 在可穿戴产品，第三季度全球市场份额排名第二。 互联网服务业务： 三季度收入73亿元，同比增长27.1%，创历史新高； 毛利率73.6%，同比提升13.1个百分点； 广告收入48亿元，同比增长44.7%； 游戏收入10亿元，同比增长25.0%。 从地区上看，三季度： 境外收入，占比高达52.4%； 小米手机在全球11个国家和地区市占率排名第一，在全球59个国家和地区市占率排名前五；在印度市场连续第16个季度保持出货量第一。 智能电动汽车和其他业务： 团队成员已超过500人，预计2024年上半年正式量产； AIoT平台已连接的IoT设备（不包括智能手机、平板及笔记本计算机）数首次突破4 亿，同比增长33.1%； 小米在中国大陆的零售店总数已突破10,000家。 小话感觉小米又交出了一份非常ok的财报，可是为啥股价大跌呢？ 想不通。 …… 最后，大家聊一聊： 你认为小米的财报ok吗？小米跌到什么时候能抄底？ 精彩留言用户可获得888社区积分噢！ $小米集团-W(01810)$","images":[{"img":"https://static.tigerbbs.com/3f5a17d57ed7aba34cdfe013be4ef460","width":"1024","height":"640"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/874394828","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"subType":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1779,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":874261442,"gmtCreate":1637793878586,"gmtModify":1637793878691,"author":{"id":"3574933488250733","authorId":"3574933488250733","name":"DoubleClick","avatar":"https://static.tigerbbs.com/91c1a51c4f84aa921e0b29d4e1b8f7e1","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574933488250733","idStr":"3574933488250733"},"themes":[],"htmlText":"我的计划是等着看","listText":"我的计划是等着看","text":"我的计划是等着看","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/874261442","repostId":"874922613","repostType":1,"repost":{"id":874922613,"gmtCreate":1637722036227,"gmtModify":1637723087352,"author":{"id":"3527667596890271","authorId":"3527667596890271","name":"Buy_Sell","avatar":"https://static.tigerbbs.com/a5f0ed79a338c758a22e0b4ea13bf9d2","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3527667596890271","idStr":"3527667596890271"},"themes":[],"title":"🚀【11月24日】涨跌不一，油价上演大逆转！今天什么值得买","htmlText":"聊聊今日份的交易想法，包括对于大盘走势后续的看法？看涨/看跌哪只股票、晒晒单等等。 港股市场 11月24日讯，港股三大指数开盘涨跌不一，恒指涨0.08%报24672点，国指跌0.02%报8825点，恒生科技指数跌0.1%报6317点。 盘面上，大型科技股多数延续跌势，<a target=\"_blank\" href=\"https://laohu8.com/S/09999\">$网易-S(09999)$</a> 跌2.44%，<a target=\"_blank\" href=\"https://laohu8.com/S/00700\">$腾讯控股(00700)$</a> 、<a target=\"_blank\" href=\"https://laohu8.com/S/09988\">$阿里巴巴-SW(09988)$</a> 、<a target=\"_blank\" href=\"https://laohu8.com/S/09618\">$京东集团-SW(09618)$</a> 均跌超1%，<a target=\"_blank\" href=\"https://laohu8.com/S/01024\">$快手-W(01024)$</a> 大涨4.5%；家电股、汽车股、半导体股、体育用品股、建材水泥股、燃气股普跌，内房股、保险股涨跌参半；国际油价上涨，石油股集体高开，<a target=\"_blank\" href=\"https://laohu8.com/S/00857\">$中国石油股份(00857)$</a> 涨超3%，恒大系继续走强，恒腾网络再涨3.58%。 <a target=\"_blank\" href=\"https://laohu8.com/S/01024\">$快手-W(01024)$</a> 绩后涨超4%，第三季度收入同比增33.4%，调整后净亏损48.22亿元。","listText":"聊聊今日份的交易想法，包括对于大盘走势后续的看法？看涨/看跌哪只股票、晒晒单等等。 港股市场 11月24日讯，港股三大指数开盘涨跌不一，恒指涨0.08%报24672点，国指跌0.02%报8825点，恒生科技指数跌0.1%报6317点。 盘面上，大型科技股多数延续跌势，<a target=\"_blank\" href=\"https://laohu8.com/S/09999\">$网易-S(09999)$</a> 跌2.44%，<a target=\"_blank\" href=\"https://laohu8.com/S/00700\">$腾讯控股(00700)$</a> 、<a target=\"_blank\" href=\"https://laohu8.com/S/09988\">$阿里巴巴-SW(09988)$</a> 、<a target=\"_blank\" href=\"https://laohu8.com/S/09618\">$京东集团-SW(09618)$</a> 均跌超1%，<a target=\"_blank\" href=\"https://laohu8.com/S/01024\">$快手-W(01024)$</a> 大涨4.5%；家电股、汽车股、半导体股、体育用品股、建材水泥股、燃气股普跌，内房股、保险股涨跌参半；国际油价上涨，石油股集体高开，<a target=\"_blank\" href=\"https://laohu8.com/S/00857\">$中国石油股份(00857)$</a> 涨超3%，恒大系继续走强，恒腾网络再涨3.58%。 <a target=\"_blank\" href=\"https://laohu8.com/S/01024\">$快手-W(01024)$</a> 绩后涨超4%，第三季度收入同比增33.4%，调整后净亏损48.22亿元。","text":"聊聊今日份的交易想法，包括对于大盘走势后续的看法？看涨/看跌哪只股票、晒晒单等等。 港股市场 11月24日讯，港股三大指数开盘涨跌不一，恒指涨0.08%报24672点，国指跌0.02%报8825点，恒生科技指数跌0.1%报6317点。 盘面上，大型科技股多数延续跌势，$网易-S(09999)$ 跌2.44%，$腾讯控股(00700)$ 、$阿里巴巴-SW(09988)$ 、$京东集团-SW(09618)$ 均跌超1%，$快手-W(01024)$ 大涨4.5%；家电股、汽车股、半导体股、体育用品股、建材水泥股、燃气股普跌，内房股、保险股涨跌参半；国际油价上涨，石油股集体高开，$中国石油股份(00857)$ 涨超3%，恒大系继续走强，恒腾网络再涨3.58%。 $快手-W(01024)$ 绩后涨超4%，第三季度收入同比增33.4%，调整后净亏损48.22亿元。","images":[{"img":"https://static.tigerbbs.com/8c224c9889536a14f83eca563ae0bb07","width":"666","height":"284"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/874922613","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"subType":2,"comments":[],"imageCount":2,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1766,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":875615904,"gmtCreate":1637642120721,"gmtModify":1637642124644,"author":{"id":"3574933488250733","authorId":"3574933488250733","name":"DoubleClick","avatar":"https://static.tigerbbs.com/91c1a51c4f84aa921e0b29d4e1b8f7e1","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574933488250733","idStr":"3574933488250733"},"themes":[],"htmlText":"[Cool]&nbsp;","listText":"[Cool]&nbsp;","text":"[Cool]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875615904","repostId":"1107351089","repostType":4,"isVote":1,"tweetType":1,"viewCount":1686,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":872837844,"gmtCreate":1637471088221,"gmtModify":1637471088326,"author":{"id":"3574933488250733","authorId":"3574933488250733","name":"DoubleClick","avatar":"https://static.tigerbbs.com/91c1a51c4f84aa921e0b29d4e1b8f7e1","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574933488250733","idStr":"3574933488250733"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Ride the upward momentum!","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Ride the upward momentum!","text":"$Apple(AAPL)$Ride the upward momentum!","images":[{"img":"https://static.tigerbbs.com/5fa407a19830d6fd52b2503f25ec1c6b","width":"750","height":"2298"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/872837844","isVote":1,"tweetType":1,"viewCount":2549,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":878020564,"gmtCreate":1637126588784,"gmtModify":1637126588955,"author":{"id":"3574933488250733","authorId":"3574933488250733","name":"DoubleClick","avatar":"https://static.tigerbbs.com/91c1a51c4f84aa921e0b29d4e1b8f7e1","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574933488250733","idStr":"3574933488250733"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/IQ\">$iQiyi Inc.(IQ)$</a>For long term play? 💎✊🏻","listText":"<a href=\"https://laohu8.com/S/IQ\">$iQiyi Inc.(IQ)$</a>For long term play? 💎✊🏻","text":"$iQiyi Inc.(IQ)$For long term play? 💎✊🏻","images":[{"img":"https://static.tigerbbs.com/bf5a60bc4debb04026b17b9cdc2ecc62","width":"750","height":"2443"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":11,"repostSize":0,"link":"https://laohu8.com/post/878020564","isVote":1,"tweetType":1,"viewCount":1477,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":873789420,"gmtCreate":1636987209261,"gmtModify":1636987209401,"author":{"id":"3574933488250733","authorId":"3574933488250733","name":"DoubleClick","avatar":"https://static.tigerbbs.com/91c1a51c4f84aa921e0b29d4e1b8f7e1","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574933488250733","idStr":"3574933488250733"},"themes":[],"htmlText":"Here for the coins!","listText":"Here for the coins!","text":"Here for the coins!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/873789420","repostId":"873287761","repostType":1,"repost":{"id":873287761,"gmtCreate":1636948480350,"gmtModify":1636957657847,"author":{"id":"3527667583497005","authorId":"3527667583497005","name":"期权异动观察","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3527667583497005","idStr":"3527667583497005"},"themes":[],"title":"11.15期权异动观察，AMD反复异动","htmlText":"<a target=\"_blank\" href=\"https://laohu8.com/S/ACB\">$奥罗拉大麻公司(ACB)$</a>&nbsp;在<a target=\"_blank\" href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a> 的带动下，周五大麻股出现了集体异动，ACB公司评级获得了部分评级机构上调，后续走势看大麻bank整体走势。坎托菲茨杰拉德公司：维持Aurora Cannabis Inc(ACB.US)中性评级, 目标价由9.60美元调整至10.75美元。 <a target=\"_blank\" href=\"https://laohu8.com/S/AMD\">$AMD(AMD)$</a> 最近股价频繁异动，消息面趋于平静，股价依然处于强势状态。 <a target=\"_blank\" href=\"https://laohu8.com/S/ATVI\">$动视暴雪(ATVI)$</a>财报不及预期暴跌之后，最近走稳开始向上拉升， 消息面平静。 <a target=\"_blank\" href=\"https://laohu8.com/S/TTD\">$Trade Desk Inc.(TTD)$</a>最近也是二次异动，该股依然处于强势上攻，奥本海默在11.9日将公司的目标价从95美元上调至100美元。 <a target=\"_blank\" href=\"https://laohu8.com/S/TSLA\">$特斯拉(TSLA)$</a> 上周下跌15%，马斯克持续减持股份，短期走势看震荡，目测这个月马斯克就可以将手里的股份减持完毕。 <a href=\"https://laohu8.com/TW/854739948\" target=\"_blank\">目前模拟账户也已经上线了期权交易功能，</a>","listText":"<a target=\"_blank\" href=\"https://laohu8.com/S/ACB\">$奥罗拉大麻公司(ACB)$</a>&nbsp;在<a target=\"_blank\" href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a> 的带动下，周五大麻股出现了集体异动，ACB公司评级获得了部分评级机构上调，后续走势看大麻bank整体走势。坎托菲茨杰拉德公司：维持Aurora Cannabis Inc(ACB.US)中性评级, 目标价由9.60美元调整至10.75美元。 <a target=\"_blank\" href=\"https://laohu8.com/S/AMD\">$AMD(AMD)$</a> 最近股价频繁异动，消息面趋于平静，股价依然处于强势状态。 <a target=\"_blank\" href=\"https://laohu8.com/S/ATVI\">$动视暴雪(ATVI)$</a>财报不及预期暴跌之后，最近走稳开始向上拉升， 消息面平静。 <a target=\"_blank\" href=\"https://laohu8.com/S/TTD\">$Trade Desk Inc.(TTD)$</a>最近也是二次异动，该股依然处于强势上攻，奥本海默在11.9日将公司的目标价从95美元上调至100美元。 <a target=\"_blank\" href=\"https://laohu8.com/S/TSLA\">$特斯拉(TSLA)$</a> 上周下跌15%，马斯克持续减持股份，短期走势看震荡，目测这个月马斯克就可以将手里的股份减持完毕。 <a href=\"https://laohu8.com/TW/854739948\" target=\"_blank\">目前模拟账户也已经上线了期权交易功能，</a>","text":"$奥罗拉大麻公司(ACB)$ 在$Sundial Growers Inc.(SNDL)$ 的带动下，周五大麻股出现了集体异动，ACB公司评级获得了部分评级机构上调，后续走势看大麻bank整体走势。坎托菲茨杰拉德公司：维持Aurora Cannabis Inc(ACB.US)中性评级, 目标价由9.60美元调整至10.75美元。 $AMD(AMD)$ 最近股价频繁异动，消息面趋于平静，股价依然处于强势状态。 $动视暴雪(ATVI)$财报不及预期暴跌之后，最近走稳开始向上拉升， 消息面平静。 $Trade Desk Inc.(TTD)$最近也是二次异动，该股依然处于强势上攻，奥本海默在11.9日将公司的目标价从95美元上调至100美元。 $特斯拉(TSLA)$ 上周下跌15%，马斯克持续减持股份，短期走势看震荡，目测这个月马斯克就可以将手里的股份减持完毕。 目前模拟账户也已经上线了期权交易功能，","images":[{"img":"https://static.tigerbbs.com/913d99ad732154469e49fa9467361f77","width":"799","height":"698"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/873287761","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1229,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":870345013,"gmtCreate":1636590325446,"gmtModify":1636590325446,"author":{"id":"3574933488250733","authorId":"3574933488250733","name":"DoubleClick","avatar":"https://static.tigerbbs.com/91c1a51c4f84aa921e0b29d4e1b8f7e1","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574933488250733","idStr":"3574933488250733"},"themes":[],"htmlText":"Lol need more words in the thesaurus for “drop”.&nbsp;","listText":"Lol need more words in the thesaurus for “drop”.&nbsp;","text":"Lol need more words in the thesaurus for “drop”.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/870345013","repostId":"1163617251","repostType":2,"repost":{"id":"1163617251","kind":"news","pubTimestamp":1636589713,"share":"https://www.laohu8.com/m/news/1163617251?lang=zh_CN&edition=full","pubTime":"2021-11-11 08:15","market":"sg","language":"en","title":"Continued Consolidation Called For Singapore Shares<blockquote>新加坡股市需要持续整合</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1163617251","media":"RTTNews","summary":"(RTTNews) - The Singapore stock market has finished lower in two straight sessions, dropping more th","content":"<p>(RTTNews) - The Singapore stock market has finished lower in two straight sessions, dropping more than 30 points or 1 percent along the way. The Straits Times Index now sits just above the 3,230-point plateau and it may extend its losses on Thursday.</p><p><blockquote>新加坡股市连续两个交易日收低，跌幅超过30点或1%。海峡时报指数目前略高于3,230点的高位，周四可能会扩大跌幅。</blockquote></p><p> The global forecast for the Asian markets suggests consolidation on inflation concerns and a drop in crude oil prices. The European markets were up and the U.S. bourses were down and the Asian markets figure to follow the latter lead.</p><p><blockquote>对亚洲市场的全球预测表明，通胀担忧和原油价格下跌将导致盘整。欧洲股市上涨，美国股市下跌，亚洲市场预计将追随后者的走势。</blockquote></p><p> The STI finished modestly lower on Wednesday following losses from the financial shares, property stocks and industrial issues.</p><p><blockquote>在金融股、房地产股和工业股下跌后，海指周三小幅收低。</blockquote></p><p> For the day, the index shed 12.10 points or 0.37 percent to finish at 3,231.32 after trading between 3,218.31 and 3,246.00. Volume was 2.03 billion shares worth 1.05 billion Singapore dollars. There were 256 decliners and 204 gainers.</p><p><blockquote>当天，该指数在3,218.31点至3,246.00点之间交易后，下跌12.10点或0.37%，收于3,231.32点。成交量为20.3亿股，价值10.5亿新元。下跌股256家，上涨股204家。</blockquote></p><p> Among the actives, Ascendas REIT fell 0.32 percent, while <a href=\"https://laohu8.com/S/CHCO\">City</a> Developments rose 0.28 percent, Comfort DelGro and DBS Group both skidded 0.62 percent, Dairy Farm International plummeted 1.17 percent, Jardine Cycle advanced 1.02 percent, Jardine Matheson climbed 1.16 percent, Mapletree Commercial Trust dropped 0.47 percent, Mapletree Logistics Trust sank 0.51 percent, Oversea-Chinese Banking Corporation lost 0.34 percent, SATS surrendered 0.95 percent, SembCorp Industries tumbled 0.96 percent, Singapore Airlines tanked 1.09 percent, Singapore Exchange eased 0.21 percent, Singapore Technologies Engineering gained 0.79 percent, SingTel declined 0.78 percent, <a href=\"https://laohu8.com/S/UBNK\">United</a> Overseas Bank retreated 0.75 percent, Wilmar International plunged 1.14 percent, Yangzijiang Shipbuilding added 0.80 percent and Keppel Corp, Genting Singapore, CapitaLand, CapitaLand Integrated Commercial Trust, Thai Beverage and Singapore Press Holdings were unchanged.</p><p><blockquote>活跃股中，腾飞房地产投资信托下跌0.32%，而<a href=\"https://laohu8.com/S/CHCO\">城市</a>Developments上涨0.28%，Comfort DelGro和DBS Group均下跌0.62%，Dairy Farm International暴跌1.17%，Jardine Cycle上涨1.02%，Jardine Matheson上涨1.16%，丰树商业信托下跌0.47%，丰树物流信托下跌0.51%，华侨银行下跌0.34%，SATS退保0.95%，胜科工业下跌0.96%，新加坡航空下跌1.09%，新加坡交易所下跌0.21%，新加坡技术工程上涨0.79%，新加坡电信下跌0.78%，<a href=\"https://laohu8.com/S/UBNK\">团结的</a>海外银行下跌0.75%，丰益国际下跌1.14%，扬子江船业上涨0.80%，吉宝企业、云顶新加坡、凯德置地、凯德综合商业信托、泰国饮料和新加坡报业控股持平。</blockquote></p><p> The lead from Wall Street is broadly negative as the major averages opened slightly lower on Wednesday but saw the losses accelerate as the day progressed to finish solidly under water.</p><p><blockquote>华尔街的领先优势普遍为负面，主要股指周三开盘小幅走低，但随着当天的进展，跌幅加速，最终在水下收盘。</blockquote></p><p> The Dow tumbled 240.04 points or 0.66 percent to finish at 36,079.94, while the NASDAQ plunged 263.84 points or 1.66 percent to close at 15,622.71 and the S&amp;P 500 sank 38.54 points or 0.82 percent to end at 4,646.71.</p><p><blockquote>道琼斯指数下跌240.04点，跌幅0.66%，收于36,079.94点；纳斯达克下跌263.84点，跌幅1.66%，收于15,622.71点；标普500下跌38.54点，跌幅0.82%，收于4,646.71点。</blockquote></p><p> Concerns about inflation contributed to the weakness on Wall Street after the Labor Department released a report showing consumer prices increased by more than expected in October, lifting the annual rate of price growth to its highest level in over thirty years.</p><p><blockquote>美国劳工部发布报告显示，10月份消费者价格涨幅超出预期，将物价年增长率提升至三十多年来的最高水平，对通胀的担忧导致华尔街疲软。</blockquote></p><p> The acceleration in the rate of consumer price inflation raised concerns about the outlook for interest rates even though the Federal Reserve has signaled it will not be in a hurry to begin raising rates.</p><p><blockquote>尽管美联储已表示不会急于开始加息，但消费者价格通胀率的加速引发了人们对利率前景的担忧。</blockquote></p><p> Also, a separate report from the Labor Department showed another modest decrease in first-time claims for U.S. unemployment benefits last week.</p><p><blockquote>此外，劳工部的另一份报告显示，上周美国首次申请失业救济人数再次小幅下降。</blockquote></p><p> Crude oil prices declined sharply on Wednesday, snapping a three-day winning streak after data showed an increase in U.S. crude stockpiles last week. <a href=\"https://laohu8.com/S/WSTC\">West</a> Texas Intermediate Crude oil futures for December ended down by $2.81 or 3.3 percent at $81.34 a barrel.</p><p><blockquote>在数据显示上周美国原油库存增加后，原油价格周三大幅下跌，结束了连续三天的上涨。<a href=\"https://laohu8.com/S/WSTC\">西方</a>德州中质原油12月期货收跌2.81美元或3.3%，报每桶81.34美元。</blockquote></p><p></p>","source":"lsy1603171495471","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Continued Consolidation Called For Singapore Shares<blockquote>新加坡股市需要持续整合</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nContinued Consolidation Called For Singapore Shares<blockquote>新加坡股市需要持续整合</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">RTTNews</strong><span class=\"h-time small\">2021-11-11 08:15</span>\n</p>\n</h4>\n</header>\n<article>\n<p>(RTTNews) - The Singapore stock market has finished lower in two straight sessions, dropping more than 30 points or 1 percent along the way. The Straits Times Index now sits just above the 3,230-point plateau and it may extend its losses on Thursday.</p><p><blockquote>新加坡股市连续两个交易日收低，跌幅超过30点或1%。海峡时报指数目前略高于3,230点的高位，周四可能会扩大跌幅。</blockquote></p><p> The global forecast for the Asian markets suggests consolidation on inflation concerns and a drop in crude oil prices. The European markets were up and the U.S. bourses were down and the Asian markets figure to follow the latter lead.</p><p><blockquote>对亚洲市场的全球预测表明，通胀担忧和原油价格下跌将导致盘整。欧洲股市上涨，美国股市下跌，亚洲市场预计将追随后者的走势。</blockquote></p><p> The STI finished modestly lower on Wednesday following losses from the financial shares, property stocks and industrial issues.</p><p><blockquote>在金融股、房地产股和工业股下跌后，海指周三小幅收低。</blockquote></p><p> For the day, the index shed 12.10 points or 0.37 percent to finish at 3,231.32 after trading between 3,218.31 and 3,246.00. Volume was 2.03 billion shares worth 1.05 billion Singapore dollars. There were 256 decliners and 204 gainers.</p><p><blockquote>当天，该指数在3,218.31点至3,246.00点之间交易后，下跌12.10点或0.37%，收于3,231.32点。成交量为20.3亿股，价值10.5亿新元。下跌股256家，上涨股204家。</blockquote></p><p> Among the actives, Ascendas REIT fell 0.32 percent, while <a href=\"https://laohu8.com/S/CHCO\">City</a> Developments rose 0.28 percent, Comfort DelGro and DBS Group both skidded 0.62 percent, Dairy Farm International plummeted 1.17 percent, Jardine Cycle advanced 1.02 percent, Jardine Matheson climbed 1.16 percent, Mapletree Commercial Trust dropped 0.47 percent, Mapletree Logistics Trust sank 0.51 percent, Oversea-Chinese Banking Corporation lost 0.34 percent, SATS surrendered 0.95 percent, SembCorp Industries tumbled 0.96 percent, Singapore Airlines tanked 1.09 percent, Singapore Exchange eased 0.21 percent, Singapore Technologies Engineering gained 0.79 percent, SingTel declined 0.78 percent, <a href=\"https://laohu8.com/S/UBNK\">United</a> Overseas Bank retreated 0.75 percent, Wilmar International plunged 1.14 percent, Yangzijiang Shipbuilding added 0.80 percent and Keppel Corp, Genting Singapore, CapitaLand, CapitaLand Integrated Commercial Trust, Thai Beverage and Singapore Press Holdings were unchanged.</p><p><blockquote>活跃股中，腾飞房地产投资信托下跌0.32%，而<a href=\"https://laohu8.com/S/CHCO\">城市</a>Developments上涨0.28%，Comfort DelGro和DBS Group均下跌0.62%，Dairy Farm International暴跌1.17%，Jardine Cycle上涨1.02%，Jardine Matheson上涨1.16%，丰树商业信托下跌0.47%，丰树物流信托下跌0.51%，华侨银行下跌0.34%，SATS退保0.95%，胜科工业下跌0.96%，新加坡航空下跌1.09%，新加坡交易所下跌0.21%，新加坡技术工程上涨0.79%，新加坡电信下跌0.78%，<a href=\"https://laohu8.com/S/UBNK\">团结的</a>海外银行下跌0.75%，丰益国际下跌1.14%，扬子江船业上涨0.80%，吉宝企业、云顶新加坡、凯德置地、凯德综合商业信托、泰国饮料和新加坡报业控股持平。</blockquote></p><p> The lead from Wall Street is broadly negative as the major averages opened slightly lower on Wednesday but saw the losses accelerate as the day progressed to finish solidly under water.</p><p><blockquote>华尔街的领先优势普遍为负面，主要股指周三开盘小幅走低，但随着当天的进展，跌幅加速，最终在水下收盘。</blockquote></p><p> The Dow tumbled 240.04 points or 0.66 percent to finish at 36,079.94, while the NASDAQ plunged 263.84 points or 1.66 percent to close at 15,622.71 and the S&amp;P 500 sank 38.54 points or 0.82 percent to end at 4,646.71.</p><p><blockquote>道琼斯指数下跌240.04点，跌幅0.66%，收于36,079.94点；纳斯达克下跌263.84点，跌幅1.66%，收于15,622.71点；标普500下跌38.54点，跌幅0.82%，收于4,646.71点。</blockquote></p><p> Concerns about inflation contributed to the weakness on Wall Street after the Labor Department released a report showing consumer prices increased by more than expected in October, lifting the annual rate of price growth to its highest level in over thirty years.</p><p><blockquote>美国劳工部发布报告显示，10月份消费者价格涨幅超出预期，将物价年增长率提升至三十多年来的最高水平，对通胀的担忧导致华尔街疲软。</blockquote></p><p> The acceleration in the rate of consumer price inflation raised concerns about the outlook for interest rates even though the Federal Reserve has signaled it will not be in a hurry to begin raising rates.</p><p><blockquote>尽管美联储已表示不会急于开始加息，但消费者价格通胀率的加速引发了人们对利率前景的担忧。</blockquote></p><p> Also, a separate report from the Labor Department showed another modest decrease in first-time claims for U.S. unemployment benefits last week.</p><p><blockquote>此外，劳工部的另一份报告显示，上周美国首次申请失业救济人数再次小幅下降。</blockquote></p><p> Crude oil prices declined sharply on Wednesday, snapping a three-day winning streak after data showed an increase in U.S. crude stockpiles last week. <a href=\"https://laohu8.com/S/WSTC\">West</a> Texas Intermediate Crude oil futures for December ended down by $2.81 or 3.3 percent at $81.34 a barrel.</p><p><blockquote>在数据显示上周美国原油库存增加后，原油价格周三大幅下跌，结束了连续三天的上涨。<a href=\"https://laohu8.com/S/WSTC\">西方</a>德州中质原油12月期货收跌2.81美元或3.3%，报每桶81.34美元。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.nasdaq.com/articles/continued-consolidation-called-for-singapore-shares\">RTTNews</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.nasdaq.com/articles/continued-consolidation-called-for-singapore-shares","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1163617251","content_text":"(RTTNews) - The Singapore stock market has finished lower in two straight sessions, dropping more than 30 points or 1 percent along the way. The Straits Times Index now sits just above the 3,230-point plateau and it may extend its losses on Thursday.\nThe global forecast for the Asian markets suggests consolidation on inflation concerns and a drop in crude oil prices. The European markets were up and the U.S. bourses were down and the Asian markets figure to follow the latter lead.\nThe STI finished modestly lower on Wednesday following losses from the financial shares, property stocks and industrial issues.\nFor the day, the index shed 12.10 points or 0.37 percent to finish at 3,231.32 after trading between 3,218.31 and 3,246.00. Volume was 2.03 billion shares worth 1.05 billion Singapore dollars. There were 256 decliners and 204 gainers.\nAmong the actives, Ascendas REIT fell 0.32 percent, while City Developments rose 0.28 percent, Comfort DelGro and DBS Group both skidded 0.62 percent, Dairy Farm International plummeted 1.17 percent, Jardine Cycle advanced 1.02 percent, Jardine Matheson climbed 1.16 percent, Mapletree Commercial Trust dropped 0.47 percent, Mapletree Logistics Trust sank 0.51 percent, Oversea-Chinese Banking Corporation lost 0.34 percent, SATS surrendered 0.95 percent, SembCorp Industries tumbled 0.96 percent, Singapore Airlines tanked 1.09 percent, Singapore Exchange eased 0.21 percent, Singapore Technologies Engineering gained 0.79 percent, SingTel declined 0.78 percent, United Overseas Bank retreated 0.75 percent, Wilmar International plunged 1.14 percent, Yangzijiang Shipbuilding added 0.80 percent and Keppel Corp, Genting Singapore, CapitaLand, CapitaLand Integrated Commercial Trust, Thai Beverage and Singapore Press Holdings were unchanged.\nThe lead from Wall Street is broadly negative as the major averages opened slightly lower on Wednesday but saw the losses accelerate as the day progressed to finish solidly under water.\nThe Dow tumbled 240.04 points or 0.66 percent to finish at 36,079.94, while the NASDAQ plunged 263.84 points or 1.66 percent to close at 15,622.71 and the S&P 500 sank 38.54 points or 0.82 percent to end at 4,646.71.\nConcerns about inflation contributed to the weakness on Wall Street after the Labor Department released a report showing consumer prices increased by more than expected in October, lifting the annual rate of price growth to its highest level in over thirty years.\nThe acceleration in the rate of consumer price inflation raised concerns about the outlook for interest rates even though the Federal Reserve has signaled it will not be in a hurry to begin raising rates.\nAlso, a separate report from the Labor Department showed another modest decrease in first-time claims for U.S. unemployment benefits last week.\nCrude oil prices declined sharply on Wednesday, snapping a three-day winning streak after data showed an increase in U.S. crude stockpiles last week. West Texas Intermediate Crude oil futures for December ended down by $2.81 or 3.3 percent at $81.34 a barrel.","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":1826,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":848639075,"gmtCreate":1635993150614,"gmtModify":1635993150735,"author":{"id":"3574933488250733","authorId":"3574933488250733","name":"DoubleClick","avatar":"https://static.tigerbbs.com/91c1a51c4f84aa921e0b29d4e1b8f7e1","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574933488250733","idStr":"3574933488250733"},"themes":[],"htmlText":"Happy Diwali Everyone!&nbsp;","listText":"Happy Diwali Everyone!&nbsp;","text":"Happy Diwali Everyone!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/848639075","isVote":1,"tweetType":1,"viewCount":1612,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":849880046,"gmtCreate":1635741983209,"gmtModify":1635741983209,"author":{"id":"3574933488250733","authorId":"3574933488250733","name":"DoubleClick","avatar":"https://static.tigerbbs.com/91c1a51c4f84aa921e0b29d4e1b8f7e1","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574933488250733","idStr":"3574933488250733"},"themes":[],"htmlText":"Nice!","listText":"Nice!","text":"Nice!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/849880046","repostId":"1164035523","repostType":2,"repost":{"id":"1164035523","kind":"news","pubTimestamp":1635736469,"share":"https://www.laohu8.com/m/news/1164035523?lang=zh_CN&edition=full","pubTime":"2021-11-01 11:14","market":"us","language":"en","title":"2 Growth Stocks That Could Deliver 1,000% Returns<blockquote>2只可带来1,000%回报的成长型股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1164035523","media":"Motley Fool","summary":"Thanks to the ongoing innovation revolutions in both the tech and healthcare sectors, shareholders h","content":"<p>Thanks to the ongoing innovation revolutions in both the tech and healthcare sectors, shareholders have been enjoying historic returns on capital over the past decade. For example, the central nervous system disorder drug specialist&nbsp;<b>Axsome Therapeutics</b>, the cancer specialist&nbsp;<b>Exelixis</b>, and the electric car pioneer&nbsp;<b>Tesla</b>&nbsp;have all delivered tenfold returns for investors who bought these names at their low points.</p><p><blockquote>由于科技和医疗保健领域持续的创新革命，股东在过去十年中一直享受着历史性的资本回报。例如，中枢神经系统疾病药物专家<b>轴体疗法</b>，癌症专家<b>Exelixis</b>，以及电动汽车先驱<b>特斯拉</b>都为在低点买入这些股票的投资者带来了十倍的回报。</blockquote></p><p> Which stocks might be the next Axsome, Exelixis, or Tesla from a growth standpoint? The cancer/rare disease specialist&nbsp;<b>Mereo BioPharma Group</b>(NASDAQ:MREO)and the diabetes-focused medical device company&nbsp;<b>Senseonics Holdings</b>(NYSEMKT:SENS)could both be gearing up for a monstrous run higher soon. In fact, these two low-priced&nbsp;healthcare stocks&nbsp;have a decent shot at generating 1,000%-plus returns for their shareholders within the next two to three years.</p><p><blockquote>从增长的角度来看，哪些股票可能成为下一个Axsome、Exelixis或特斯拉？癌症/罕见病专家<b>Mereo生物制药集团</b>（纳斯达克：MREO）和专注于糖尿病的医疗器械公司<b>Senseonics控股</b>(NYSEMKT：SENS)两者都可能很快就会为大幅走高做准备。事实上，这两只低价医疗保健股很有可能在未来两到三年内为股东带来1,000%以上的回报。</blockquote></p><p> Here's a brief overview on the risks and potential rewards associated with each of these promising growth vehicles.</p><p><blockquote>以下是与这些有前途的增长工具相关的风险和潜在回报的简要概述。</blockquote></p><p> <b>Mereo BioPharma: A bet on the future of immunotherapy</b></p><p><blockquote><b>Mereo BioPharma：押注免疫疗法的未来</b></blockquote></p><p> The London-based biopharma Mereo hasn't exactly set the world on fire since its American depository shares (ADS) made their debut on the Nasdaq stock exchange. Keeping with this theme, the biotech's ADSes have lost approximately 65% of their value since April 2019. This steady downward trend shouldn't scare away aggressive investors, however. Mereo's plunging share price, after all, is more about Mr. Market's well-known impatience with clinical-stage biotechs, rather than the company's underlying value proposition.</p><p><blockquote>自其美国存托股票(ADS)在纳斯达克证券交易所首次亮相以来，总部位于伦敦的生物制药公司Mereo并没有真正引起轰动。与这一主题保持一致，自2019年4月以来，该生物技术公司的ADSE已损失约65%的价值。然而，这种稳定的下降趋势不应吓跑激进的投资者。毕竟，Mereo股价暴跌更多的是市场先生对临床阶段生物技术众所周知的不耐烦，而不是该公司的潜在价值主张。</blockquote></p><p> What's the scoop? Mereo is a small-cap company with six assets under development for both cancer and rare diseases. However, the one drug candidate that could undoubtedly send the company's shares rocketing higher is the&nbsp;anti-TIGIT therapy&nbsp;known as etigilimab. Several major drug companies, such as&nbsp;<b>BeiGene</b>,<b>Bristol Myers Squibb</b>,<b>Merck</b>, and&nbsp;<b>Roche</b>, have anti-TIGIT therapies under development due to their potential to boost the efficacy and durability of cancer immunotherapy treatments in general. Mereo's etigilimab is currently in a combined phase 1/2 basket study to evaluate its utility as part of combination treament, along with Bristol's megablockbuster checkpoint inhibitor Opdivo, for a variety of solid tumors.</p><p><blockquote>有什么独家新闻？Mereo是一家小型公司，拥有六项正在开发的癌症和罕见疾病资产。然而，一种无疑可能推动该公司股价飙升的候选药物是名为etigilimab的抗TIGIT疗法。几大药企，如<b>百济神州</b>,<b>百时美施贵宝</b>,<b>默克</b>，和<b>罗氏</b>由于抗TIGIT疗法通常具有增强癌症免疫疗法的功效和持久性的潜力，因此正在开发抗TIGIT疗法。Mereo的etigilimab目前正在进行一项联合1/2期篮子研究，以评估其作为联合治疗的一部分，与Bristol的megablockbuster检查点抑制剂Opdivo一起用于多种实体瘤。</blockquote></p><p> As things stand now, Mereo's anti-TIGIT candidate is slated to yield top-line data from this basket trial in approximately 18-months from now. During this lengthy interval, however, the drugmaker ought to provide multiple updates on etigilimab's progress, which could turn out to be a series of major catalysts for its share price in the coming months. Another bit of good news is that Mereo's cash runway reportedly extends into 2024. That's key, because it means that the biotech shouldn't have to repeatly tap the public markets for capital over the next year and a half.</p><p><blockquote>就目前情况而言，Mereo的抗TIGIT候选药物预计将在大约18个月后从这项篮子试验中产生顶线数据。然而，在这段漫长的时间间隔内，该制药商应该提供有关etigilimab进展的多项最新信息，这可能会成为未来几个月其股价的一系列主要催化剂。另一个好消息是，据报道Mereo的现金跑道将延伸至2024年。这是关键，因为这意味着生物技术公司不应该在未来一年半内反复利用公开市场获取资本。</blockquote></p><p> What's the downside risk? Mereo's management team has been open about its desire to partner with larger biopharmas. Etigilimab, for its part, could spark either a high dollar licensing agreement or a full-on buyout within the next two years. So a lot is riding on this single experimental drug. Unfortunately, early stage cancer therapies fail more often than not in the clinic. As a failure in this case would weigh heavily on the biotech's share price, potential investors may want to keep any initial position on the small side.</p><p><blockquote>下行风险是什么？Mereo的管理团队一直公开表示希望与大型生物制药公司合作。就Etigilimab而言，它可能会在未来两年内引发高额许可协议或全面收购。所以很大程度上取决于这种单一的实验药物。不幸的是，早期癌症疗法在临床上经常失败。由于这种情况下的失败将严重影响生物技术公司的股价，潜在投资者可能希望将初始头寸保持在较小的水平。</blockquote></p><p> <b>Senseonic: A rising tide lifts all boats</b></p><p><blockquote><b>Senseonic：水涨船高</b></blockquote></p><p> Senseonics' stock is worth a look by ultra-aggressive investors due to its implantable continuous glucose monitoring (CGM) device franchise known as Eversense. The lowdown is that the CGM market has been growing by over 10%&nbsp;<i>per year</i>&nbsp;over the past five years, according to a report by Grand View Research. What's more, this space is forecast to grow by at least 10% per year over the next five years. That's definitely a favorable trend for a small-cap CGM player like Senseonics.</p><p><blockquote>Senseonics的股票值得超级激进的投资者关注，因为它拥有名为Eversense的植入式连续血糖监测(CGM)设备专营权。真相是CGM市场增长超过10%<i>每年</i>根据Grand View Research的一份报告，在过去五年中。更重要的是，该领域预计在未来五年内每年至少增长10%。对于像Senseonics这样的小型CGM参与者来说，这绝对是一个有利的趋势。</blockquote></p><p> So far, Senseonics has only captured a&nbsp;small sliver&nbsp;of this multi-billion dollar medical device market with its Eversense franchise. But the company is hoping to drastically improve its competitive positioning with a potential regulatory approval by the Food and Drug Administration (FDA) for its 180-day version of the Eversense CGM system. The medical device company&nbsp;submitteda regulatory application to the FDA for this proposed product over a year ago. So a decision could come any day now.</p><p><blockquote>到目前为止，Senseonics仅凭借其Eversense特许经营权占领了这个价值数十亿美元的医疗设备市场的一小部分。但该公司希望通过食品和药物管理局(FDA)对其180天版本的Eversense CGM系统的潜在监管批准来大幅提高其竞争地位。该医疗器械公司一年多前就该拟议产品向FDA提交了监管申请。所以现在随时都可能做出决定。</blockquote></p><p></p><p> Why does this FDA approval matter? Senseonics' internal projections have the company's top-line rising at a compound annual growth rate of over 70% over the next five years as a result of this key regulatory nod. The long and short of it is that the current 90-day Eversense CGM system isn't particularly competitive in the U.S. against the market-leading devices from&nbsp;<b>DexCom</b>&nbsp;and&nbsp;<b>Abbott Laboratories</b>, respectively. But this longer-lasting version of the device could cause sales to skyrocket in the coming years.</p><p><blockquote>为什么FDA的批准很重要？Senseonics的内部预测显示，由于这一关键的监管批准，该公司的营收在未来五年内将以超过70%的复合年增长率增长。总而言之，目前的90天Eversense CGM系统在美国与市场领先的设备相比并没有特别的竞争力<b>DexCom</b>和<b>雅培实验室</b>，分别。但这种更耐用的设备版本可能会在未来几年导致销量飙升。</blockquote></p><p> What's the risk? Senseonics is competing in a jam-packed space against a number of well-capitalized medical-device giants. So there is a chance that this long-awaited FDA approval won't spark a parabolic rise in sales. That's not a knock against Senseonics' CGM system, but rather the harsh reality of competing against healthcare companies with vastly superior resources. Investors shouldn't ignore this potential risk factor.</p><p><blockquote>有什么风险？Senseonics正在拥挤的空间中与许多资本雄厚的医疗设备巨头竞争。因此，这一期待已久的FDA批准有可能不会引发销售额的抛物线增长。这并不是对Senseonics CGM系统的打击，而是与拥有极其优越资源的医疗保健公司竞争的残酷现实。投资者不应忽视这一潜在的风险因素。</blockquote></p><p> All told, Senseonics could be on the verge of a game-changing regulatory event that might prove to be a key inflection point for the company's CGM franchise. If true, this medical device company's stock should turn out to be a downright bargain at these levels.</p><p><blockquote>总而言之，Senseonics可能正处于改变游戏规则的监管事件的边缘，这可能会成为该公司CGM特许经营权的一个关键转折点。如果属实，这家医疗器械公司的股票在这些水平上应该会非常便宜。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Growth Stocks That Could Deliver 1,000% Returns<blockquote>2只可带来1,000%回报的成长型股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Growth Stocks That Could Deliver 1,000% Returns<blockquote>2只可带来1,000%回报的成长型股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-11-01 11:14</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Thanks to the ongoing innovation revolutions in both the tech and healthcare sectors, shareholders have been enjoying historic returns on capital over the past decade. For example, the central nervous system disorder drug specialist&nbsp;<b>Axsome Therapeutics</b>, the cancer specialist&nbsp;<b>Exelixis</b>, and the electric car pioneer&nbsp;<b>Tesla</b>&nbsp;have all delivered tenfold returns for investors who bought these names at their low points.</p><p><blockquote>由于科技和医疗保健领域持续的创新革命，股东在过去十年中一直享受着历史性的资本回报。例如，中枢神经系统疾病药物专家<b>轴体疗法</b>，癌症专家<b>Exelixis</b>，以及电动汽车先驱<b>特斯拉</b>都为在低点买入这些股票的投资者带来了十倍的回报。</blockquote></p><p> Which stocks might be the next Axsome, Exelixis, or Tesla from a growth standpoint? The cancer/rare disease specialist&nbsp;<b>Mereo BioPharma Group</b>(NASDAQ:MREO)and the diabetes-focused medical device company&nbsp;<b>Senseonics Holdings</b>(NYSEMKT:SENS)could both be gearing up for a monstrous run higher soon. In fact, these two low-priced&nbsp;healthcare stocks&nbsp;have a decent shot at generating 1,000%-plus returns for their shareholders within the next two to three years.</p><p><blockquote>从增长的角度来看，哪些股票可能成为下一个Axsome、Exelixis或特斯拉？癌症/罕见病专家<b>Mereo生物制药集团</b>（纳斯达克：MREO）和专注于糖尿病的医疗器械公司<b>Senseonics控股</b>(NYSEMKT：SENS)两者都可能很快就会为大幅走高做准备。事实上，这两只低价医疗保健股很有可能在未来两到三年内为股东带来1,000%以上的回报。</blockquote></p><p> Here's a brief overview on the risks and potential rewards associated with each of these promising growth vehicles.</p><p><blockquote>以下是与这些有前途的增长工具相关的风险和潜在回报的简要概述。</blockquote></p><p> <b>Mereo BioPharma: A bet on the future of immunotherapy</b></p><p><blockquote><b>Mereo BioPharma：押注免疫疗法的未来</b></blockquote></p><p> The London-based biopharma Mereo hasn't exactly set the world on fire since its American depository shares (ADS) made their debut on the Nasdaq stock exchange. Keeping with this theme, the biotech's ADSes have lost approximately 65% of their value since April 2019. This steady downward trend shouldn't scare away aggressive investors, however. Mereo's plunging share price, after all, is more about Mr. Market's well-known impatience with clinical-stage biotechs, rather than the company's underlying value proposition.</p><p><blockquote>自其美国存托股票(ADS)在纳斯达克证券交易所首次亮相以来，总部位于伦敦的生物制药公司Mereo并没有真正引起轰动。与这一主题保持一致，自2019年4月以来，该生物技术公司的ADSE已损失约65%的价值。然而，这种稳定的下降趋势不应吓跑激进的投资者。毕竟，Mereo股价暴跌更多的是市场先生对临床阶段生物技术众所周知的不耐烦，而不是该公司的潜在价值主张。</blockquote></p><p> What's the scoop? Mereo is a small-cap company with six assets under development for both cancer and rare diseases. However, the one drug candidate that could undoubtedly send the company's shares rocketing higher is the&nbsp;anti-TIGIT therapy&nbsp;known as etigilimab. Several major drug companies, such as&nbsp;<b>BeiGene</b>,<b>Bristol Myers Squibb</b>,<b>Merck</b>, and&nbsp;<b>Roche</b>, have anti-TIGIT therapies under development due to their potential to boost the efficacy and durability of cancer immunotherapy treatments in general. Mereo's etigilimab is currently in a combined phase 1/2 basket study to evaluate its utility as part of combination treament, along with Bristol's megablockbuster checkpoint inhibitor Opdivo, for a variety of solid tumors.</p><p><blockquote>有什么独家新闻？Mereo是一家小型公司，拥有六项正在开发的癌症和罕见疾病资产。然而，一种无疑可能推动该公司股价飙升的候选药物是名为etigilimab的抗TIGIT疗法。几大药企，如<b>百济神州</b>,<b>百时美施贵宝</b>,<b>默克</b>，和<b>罗氏</b>由于抗TIGIT疗法通常具有增强癌症免疫疗法的功效和持久性的潜力，因此正在开发抗TIGIT疗法。Mereo的etigilimab目前正在进行一项联合1/2期篮子研究，以评估其作为联合治疗的一部分，与Bristol的megablockbuster检查点抑制剂Opdivo一起用于多种实体瘤。</blockquote></p><p> As things stand now, Mereo's anti-TIGIT candidate is slated to yield top-line data from this basket trial in approximately 18-months from now. During this lengthy interval, however, the drugmaker ought to provide multiple updates on etigilimab's progress, which could turn out to be a series of major catalysts for its share price in the coming months. Another bit of good news is that Mereo's cash runway reportedly extends into 2024. That's key, because it means that the biotech shouldn't have to repeatly tap the public markets for capital over the next year and a half.</p><p><blockquote>就目前情况而言，Mereo的抗TIGIT候选药物预计将在大约18个月后从这项篮子试验中产生顶线数据。然而，在这段漫长的时间间隔内，该制药商应该提供有关etigilimab进展的多项最新信息，这可能会成为未来几个月其股价的一系列主要催化剂。另一个好消息是，据报道Mereo的现金跑道将延伸至2024年。这是关键，因为这意味着生物技术公司不应该在未来一年半内反复利用公开市场获取资本。</blockquote></p><p> What's the downside risk? Mereo's management team has been open about its desire to partner with larger biopharmas. Etigilimab, for its part, could spark either a high dollar licensing agreement or a full-on buyout within the next two years. So a lot is riding on this single experimental drug. Unfortunately, early stage cancer therapies fail more often than not in the clinic. As a failure in this case would weigh heavily on the biotech's share price, potential investors may want to keep any initial position on the small side.</p><p><blockquote>下行风险是什么？Mereo的管理团队一直公开表示希望与大型生物制药公司合作。就Etigilimab而言，它可能会在未来两年内引发高额许可协议或全面收购。所以很大程度上取决于这种单一的实验药物。不幸的是，早期癌症疗法在临床上经常失败。由于这种情况下的失败将严重影响生物技术公司的股价，潜在投资者可能希望将初始头寸保持在较小的水平。</blockquote></p><p> <b>Senseonic: A rising tide lifts all boats</b></p><p><blockquote><b>Senseonic：水涨船高</b></blockquote></p><p> Senseonics' stock is worth a look by ultra-aggressive investors due to its implantable continuous glucose monitoring (CGM) device franchise known as Eversense. The lowdown is that the CGM market has been growing by over 10%&nbsp;<i>per year</i>&nbsp;over the past five years, according to a report by Grand View Research. What's more, this space is forecast to grow by at least 10% per year over the next five years. That's definitely a favorable trend for a small-cap CGM player like Senseonics.</p><p><blockquote>Senseonics的股票值得超级激进的投资者关注，因为它拥有名为Eversense的植入式连续血糖监测(CGM)设备专营权。真相是CGM市场增长超过10%<i>每年</i>根据Grand View Research的一份报告，在过去五年中。更重要的是，该领域预计在未来五年内每年至少增长10%。对于像Senseonics这样的小型CGM参与者来说，这绝对是一个有利的趋势。</blockquote></p><p> So far, Senseonics has only captured a&nbsp;small sliver&nbsp;of this multi-billion dollar medical device market with its Eversense franchise. But the company is hoping to drastically improve its competitive positioning with a potential regulatory approval by the Food and Drug Administration (FDA) for its 180-day version of the Eversense CGM system. The medical device company&nbsp;submitteda regulatory application to the FDA for this proposed product over a year ago. So a decision could come any day now.</p><p><blockquote>到目前为止，Senseonics仅凭借其Eversense特许经营权占领了这个价值数十亿美元的医疗设备市场的一小部分。但该公司希望通过食品和药物管理局(FDA)对其180天版本的Eversense CGM系统的潜在监管批准来大幅提高其竞争地位。该医疗器械公司一年多前就该拟议产品向FDA提交了监管申请。所以现在随时都可能做出决定。</blockquote></p><p></p><p> Why does this FDA approval matter? Senseonics' internal projections have the company's top-line rising at a compound annual growth rate of over 70% over the next five years as a result of this key regulatory nod. The long and short of it is that the current 90-day Eversense CGM system isn't particularly competitive in the U.S. against the market-leading devices from&nbsp;<b>DexCom</b>&nbsp;and&nbsp;<b>Abbott Laboratories</b>, respectively. But this longer-lasting version of the device could cause sales to skyrocket in the coming years.</p><p><blockquote>为什么FDA的批准很重要？Senseonics的内部预测显示，由于这一关键的监管批准，该公司的营收在未来五年内将以超过70%的复合年增长率增长。总而言之，目前的90天Eversense CGM系统在美国与市场领先的设备相比并没有特别的竞争力<b>DexCom</b>和<b>雅培实验室</b>，分别。但这种更耐用的设备版本可能会在未来几年导致销量飙升。</blockquote></p><p> What's the risk? Senseonics is competing in a jam-packed space against a number of well-capitalized medical-device giants. So there is a chance that this long-awaited FDA approval won't spark a parabolic rise in sales. That's not a knock against Senseonics' CGM system, but rather the harsh reality of competing against healthcare companies with vastly superior resources. Investors shouldn't ignore this potential risk factor.</p><p><blockquote>有什么风险？Senseonics正在拥挤的空间中与许多资本雄厚的医疗设备巨头竞争。因此，这一期待已久的FDA批准有可能不会引发销售额的抛物线增长。这并不是对Senseonics CGM系统的打击，而是与拥有极其优越资源的医疗保健公司竞争的残酷现实。投资者不应忽视这一潜在的风险因素。</blockquote></p><p> All told, Senseonics could be on the verge of a game-changing regulatory event that might prove to be a key inflection point for the company's CGM franchise. If true, this medical device company's stock should turn out to be a downright bargain at these levels.</p><p><blockquote>总而言之，Senseonics可能正处于改变游戏规则的监管事件的边缘，这可能会成为该公司CGM特许经营权的一个关键转折点。如果属实，这家医疗器械公司的股票在这些水平上应该会非常便宜。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/10/31/2-growth-stocks-that-could-deliver-1000-returns/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SENS":"Senseonics Holdings,Inc.","MREO":"Mereo Biopharma Group Plc"},"source_url":"https://www.fool.com/investing/2021/10/31/2-growth-stocks-that-could-deliver-1000-returns/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164035523","content_text":"Thanks to the ongoing innovation revolutions in both the tech and healthcare sectors, shareholders have been enjoying historic returns on capital over the past decade. For example, the central nervous system disorder drug specialist Axsome Therapeutics, the cancer specialist Exelixis, and the electric car pioneer Tesla have all delivered tenfold returns for investors who bought these names at their low points.\nWhich stocks might be the next Axsome, Exelixis, or Tesla from a growth standpoint? The cancer/rare disease specialist Mereo BioPharma Group(NASDAQ:MREO)and the diabetes-focused medical device company Senseonics Holdings(NYSEMKT:SENS)could both be gearing up for a monstrous run higher soon. In fact, these two low-priced healthcare stocks have a decent shot at generating 1,000%-plus returns for their shareholders within the next two to three years.\nHere's a brief overview on the risks and potential rewards associated with each of these promising growth vehicles.\nMereo BioPharma: A bet on the future of immunotherapy\nThe London-based biopharma Mereo hasn't exactly set the world on fire since its American depository shares (ADS) made their debut on the Nasdaq stock exchange. Keeping with this theme, the biotech's ADSes have lost approximately 65% of their value since April 2019. This steady downward trend shouldn't scare away aggressive investors, however. Mereo's plunging share price, after all, is more about Mr. Market's well-known impatience with clinical-stage biotechs, rather than the company's underlying value proposition.\nWhat's the scoop? Mereo is a small-cap company with six assets under development for both cancer and rare diseases. However, the one drug candidate that could undoubtedly send the company's shares rocketing higher is the anti-TIGIT therapy known as etigilimab. Several major drug companies, such as BeiGene,Bristol Myers Squibb,Merck, and Roche, have anti-TIGIT therapies under development due to their potential to boost the efficacy and durability of cancer immunotherapy treatments in general. Mereo's etigilimab is currently in a combined phase 1/2 basket study to evaluate its utility as part of combination treament, along with Bristol's megablockbuster checkpoint inhibitor Opdivo, for a variety of solid tumors.\nAs things stand now, Mereo's anti-TIGIT candidate is slated to yield top-line data from this basket trial in approximately 18-months from now. During this lengthy interval, however, the drugmaker ought to provide multiple updates on etigilimab's progress, which could turn out to be a series of major catalysts for its share price in the coming months. Another bit of good news is that Mereo's cash runway reportedly extends into 2024. That's key, because it means that the biotech shouldn't have to repeatly tap the public markets for capital over the next year and a half.\nWhat's the downside risk? Mereo's management team has been open about its desire to partner with larger biopharmas. Etigilimab, for its part, could spark either a high dollar licensing agreement or a full-on buyout within the next two years. So a lot is riding on this single experimental drug. Unfortunately, early stage cancer therapies fail more often than not in the clinic. As a failure in this case would weigh heavily on the biotech's share price, potential investors may want to keep any initial position on the small side.\nSenseonic: A rising tide lifts all boats\nSenseonics' stock is worth a look by ultra-aggressive investors due to its implantable continuous glucose monitoring (CGM) device franchise known as Eversense. The lowdown is that the CGM market has been growing by over 10% per year over the past five years, according to a report by Grand View Research. What's more, this space is forecast to grow by at least 10% per year over the next five years. That's definitely a favorable trend for a small-cap CGM player like Senseonics.\nSo far, Senseonics has only captured a small sliver of this multi-billion dollar medical device market with its Eversense franchise. But the company is hoping to drastically improve its competitive positioning with a potential regulatory approval by the Food and Drug Administration (FDA) for its 180-day version of the Eversense CGM system. The medical device company submitteda regulatory application to the FDA for this proposed product over a year ago. So a decision could come any day now.\nWhy does this FDA approval matter? Senseonics' internal projections have the company's top-line rising at a compound annual growth rate of over 70% over the next five years as a result of this key regulatory nod. The long and short of it is that the current 90-day Eversense CGM system isn't particularly competitive in the U.S. against the market-leading devices from DexCom and Abbott Laboratories, respectively. But this longer-lasting version of the device could cause sales to skyrocket in the coming years.\nWhat's the risk? Senseonics is competing in a jam-packed space against a number of well-capitalized medical-device giants. So there is a chance that this long-awaited FDA approval won't spark a parabolic rise in sales. That's not a knock against Senseonics' CGM system, but rather the harsh reality of competing against healthcare companies with vastly superior resources. Investors shouldn't ignore this potential risk factor.\nAll told, Senseonics could be on the verge of a game-changing regulatory event that might prove to be a key inflection point for the company's CGM franchise. If true, this medical device company's stock should turn out to be a downright bargain at these levels.","news_type":1,"symbols_score_info":{"SENS":0.9,"MREO":0.9}},"isVote":1,"tweetType":1,"viewCount":1972,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":164993620,"gmtCreate":1624164144060,"gmtModify":1634009935589,"author":{"id":"3574933488250733","authorId":"3574933488250733","name":"DoubleClick","avatar":"https://static.tigerbbs.com/91c1a51c4f84aa921e0b29d4e1b8f7e1","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574933488250733","idStr":"3574933488250733"},"themes":[],"htmlText":"Latest","listText":"Latest","text":"Latest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/164993620","repostId":"1126454279","repostType":2,"isVote":1,"tweetType":1,"viewCount":146,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":878020564,"gmtCreate":1637126588784,"gmtModify":1637126588955,"author":{"id":"3574933488250733","authorId":"3574933488250733","name":"DoubleClick","avatar":"https://static.tigerbbs.com/91c1a51c4f84aa921e0b29d4e1b8f7e1","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574933488250733","idStr":"3574933488250733"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/IQ\">$iQiyi Inc.(IQ)$</a>For long term play? 💎✊🏻","listText":"<a href=\"https://laohu8.com/S/IQ\">$iQiyi Inc.(IQ)$</a>For long term play? 💎✊🏻","text":"$iQiyi Inc.(IQ)$For long term play? 💎✊🏻","images":[{"img":"https://static.tigerbbs.com/bf5a60bc4debb04026b17b9cdc2ecc62","width":"750","height":"2443"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":11,"repostSize":0,"link":"https://laohu8.com/post/878020564","isVote":1,"tweetType":1,"viewCount":1477,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":872837844,"gmtCreate":1637471088221,"gmtModify":1637471088326,"author":{"id":"3574933488250733","authorId":"3574933488250733","name":"DoubleClick","avatar":"https://static.tigerbbs.com/91c1a51c4f84aa921e0b29d4e1b8f7e1","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574933488250733","idStr":"3574933488250733"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Ride the upward momentum!","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Ride the upward momentum!","text":"$Apple(AAPL)$Ride the upward momentum!","images":[{"img":"https://static.tigerbbs.com/5fa407a19830d6fd52b2503f25ec1c6b","width":"750","height":"2298"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/872837844","isVote":1,"tweetType":1,"viewCount":2549,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":870345013,"gmtCreate":1636590325446,"gmtModify":1636590325446,"author":{"id":"3574933488250733","authorId":"3574933488250733","name":"DoubleClick","avatar":"https://static.tigerbbs.com/91c1a51c4f84aa921e0b29d4e1b8f7e1","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574933488250733","idStr":"3574933488250733"},"themes":[],"htmlText":"Lol need more words in the thesaurus for “drop”.&nbsp;","listText":"Lol need more words in the thesaurus for “drop”.&nbsp;","text":"Lol need more words in the thesaurus for “drop”.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/870345013","repostId":"1163617251","repostType":2,"repost":{"id":"1163617251","kind":"news","pubTimestamp":1636589713,"share":"https://www.laohu8.com/m/news/1163617251?lang=zh_CN&edition=full","pubTime":"2021-11-11 08:15","market":"sg","language":"en","title":"Continued Consolidation Called For Singapore Shares<blockquote>新加坡股市需要持续整合</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1163617251","media":"RTTNews","summary":"(RTTNews) - The Singapore stock market has finished lower in two straight sessions, dropping more th","content":"<p>(RTTNews) - The Singapore stock market has finished lower in two straight sessions, dropping more than 30 points or 1 percent along the way. The Straits Times Index now sits just above the 3,230-point plateau and it may extend its losses on Thursday.</p><p><blockquote>新加坡股市连续两个交易日收低，跌幅超过30点或1%。海峡时报指数目前略高于3,230点的高位，周四可能会扩大跌幅。</blockquote></p><p> The global forecast for the Asian markets suggests consolidation on inflation concerns and a drop in crude oil prices. The European markets were up and the U.S. bourses were down and the Asian markets figure to follow the latter lead.</p><p><blockquote>对亚洲市场的全球预测表明，通胀担忧和原油价格下跌将导致盘整。欧洲股市上涨，美国股市下跌，亚洲市场预计将追随后者的走势。</blockquote></p><p> The STI finished modestly lower on Wednesday following losses from the financial shares, property stocks and industrial issues.</p><p><blockquote>在金融股、房地产股和工业股下跌后，海指周三小幅收低。</blockquote></p><p> For the day, the index shed 12.10 points or 0.37 percent to finish at 3,231.32 after trading between 3,218.31 and 3,246.00. Volume was 2.03 billion shares worth 1.05 billion Singapore dollars. There were 256 decliners and 204 gainers.</p><p><blockquote>当天，该指数在3,218.31点至3,246.00点之间交易后，下跌12.10点或0.37%，收于3,231.32点。成交量为20.3亿股，价值10.5亿新元。下跌股256家，上涨股204家。</blockquote></p><p> Among the actives, Ascendas REIT fell 0.32 percent, while <a href=\"https://laohu8.com/S/CHCO\">City</a> Developments rose 0.28 percent, Comfort DelGro and DBS Group both skidded 0.62 percent, Dairy Farm International plummeted 1.17 percent, Jardine Cycle advanced 1.02 percent, Jardine Matheson climbed 1.16 percent, Mapletree Commercial Trust dropped 0.47 percent, Mapletree Logistics Trust sank 0.51 percent, Oversea-Chinese Banking Corporation lost 0.34 percent, SATS surrendered 0.95 percent, SembCorp Industries tumbled 0.96 percent, Singapore Airlines tanked 1.09 percent, Singapore Exchange eased 0.21 percent, Singapore Technologies Engineering gained 0.79 percent, SingTel declined 0.78 percent, <a href=\"https://laohu8.com/S/UBNK\">United</a> Overseas Bank retreated 0.75 percent, Wilmar International plunged 1.14 percent, Yangzijiang Shipbuilding added 0.80 percent and Keppel Corp, Genting Singapore, CapitaLand, CapitaLand Integrated Commercial Trust, Thai Beverage and Singapore Press Holdings were unchanged.</p><p><blockquote>活跃股中，腾飞房地产投资信托下跌0.32%，而<a href=\"https://laohu8.com/S/CHCO\">城市</a>Developments上涨0.28%，Comfort DelGro和DBS Group均下跌0.62%，Dairy Farm International暴跌1.17%，Jardine Cycle上涨1.02%，Jardine Matheson上涨1.16%，丰树商业信托下跌0.47%，丰树物流信托下跌0.51%，华侨银行下跌0.34%，SATS退保0.95%，胜科工业下跌0.96%，新加坡航空下跌1.09%，新加坡交易所下跌0.21%，新加坡技术工程上涨0.79%，新加坡电信下跌0.78%，<a href=\"https://laohu8.com/S/UBNK\">团结的</a>海外银行下跌0.75%，丰益国际下跌1.14%，扬子江船业上涨0.80%，吉宝企业、云顶新加坡、凯德置地、凯德综合商业信托、泰国饮料和新加坡报业控股持平。</blockquote></p><p> The lead from Wall Street is broadly negative as the major averages opened slightly lower on Wednesday but saw the losses accelerate as the day progressed to finish solidly under water.</p><p><blockquote>华尔街的领先优势普遍为负面，主要股指周三开盘小幅走低，但随着当天的进展，跌幅加速，最终在水下收盘。</blockquote></p><p> The Dow tumbled 240.04 points or 0.66 percent to finish at 36,079.94, while the NASDAQ plunged 263.84 points or 1.66 percent to close at 15,622.71 and the S&amp;P 500 sank 38.54 points or 0.82 percent to end at 4,646.71.</p><p><blockquote>道琼斯指数下跌240.04点，跌幅0.66%，收于36,079.94点；纳斯达克下跌263.84点，跌幅1.66%，收于15,622.71点；标普500下跌38.54点，跌幅0.82%，收于4,646.71点。</blockquote></p><p> Concerns about inflation contributed to the weakness on Wall Street after the Labor Department released a report showing consumer prices increased by more than expected in October, lifting the annual rate of price growth to its highest level in over thirty years.</p><p><blockquote>美国劳工部发布报告显示，10月份消费者价格涨幅超出预期，将物价年增长率提升至三十多年来的最高水平，对通胀的担忧导致华尔街疲软。</blockquote></p><p> The acceleration in the rate of consumer price inflation raised concerns about the outlook for interest rates even though the Federal Reserve has signaled it will not be in a hurry to begin raising rates.</p><p><blockquote>尽管美联储已表示不会急于开始加息，但消费者价格通胀率的加速引发了人们对利率前景的担忧。</blockquote></p><p> Also, a separate report from the Labor Department showed another modest decrease in first-time claims for U.S. unemployment benefits last week.</p><p><blockquote>此外，劳工部的另一份报告显示，上周美国首次申请失业救济人数再次小幅下降。</blockquote></p><p> Crude oil prices declined sharply on Wednesday, snapping a three-day winning streak after data showed an increase in U.S. crude stockpiles last week. <a href=\"https://laohu8.com/S/WSTC\">West</a> Texas Intermediate Crude oil futures for December ended down by $2.81 or 3.3 percent at $81.34 a barrel.</p><p><blockquote>在数据显示上周美国原油库存增加后，原油价格周三大幅下跌，结束了连续三天的上涨。<a href=\"https://laohu8.com/S/WSTC\">西方</a>德州中质原油12月期货收跌2.81美元或3.3%，报每桶81.34美元。</blockquote></p><p></p>","source":"lsy1603171495471","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Continued Consolidation Called For Singapore Shares<blockquote>新加坡股市需要持续整合</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nContinued Consolidation Called For Singapore Shares<blockquote>新加坡股市需要持续整合</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">RTTNews</strong><span class=\"h-time small\">2021-11-11 08:15</span>\n</p>\n</h4>\n</header>\n<article>\n<p>(RTTNews) - The Singapore stock market has finished lower in two straight sessions, dropping more than 30 points or 1 percent along the way. The Straits Times Index now sits just above the 3,230-point plateau and it may extend its losses on Thursday.</p><p><blockquote>新加坡股市连续两个交易日收低，跌幅超过30点或1%。海峡时报指数目前略高于3,230点的高位，周四可能会扩大跌幅。</blockquote></p><p> The global forecast for the Asian markets suggests consolidation on inflation concerns and a drop in crude oil prices. The European markets were up and the U.S. bourses were down and the Asian markets figure to follow the latter lead.</p><p><blockquote>对亚洲市场的全球预测表明，通胀担忧和原油价格下跌将导致盘整。欧洲股市上涨，美国股市下跌，亚洲市场预计将追随后者的走势。</blockquote></p><p> The STI finished modestly lower on Wednesday following losses from the financial shares, property stocks and industrial issues.</p><p><blockquote>在金融股、房地产股和工业股下跌后，海指周三小幅收低。</blockquote></p><p> For the day, the index shed 12.10 points or 0.37 percent to finish at 3,231.32 after trading between 3,218.31 and 3,246.00. Volume was 2.03 billion shares worth 1.05 billion Singapore dollars. There were 256 decliners and 204 gainers.</p><p><blockquote>当天，该指数在3,218.31点至3,246.00点之间交易后，下跌12.10点或0.37%，收于3,231.32点。成交量为20.3亿股，价值10.5亿新元。下跌股256家，上涨股204家。</blockquote></p><p> Among the actives, Ascendas REIT fell 0.32 percent, while <a href=\"https://laohu8.com/S/CHCO\">City</a> Developments rose 0.28 percent, Comfort DelGro and DBS Group both skidded 0.62 percent, Dairy Farm International plummeted 1.17 percent, Jardine Cycle advanced 1.02 percent, Jardine Matheson climbed 1.16 percent, Mapletree Commercial Trust dropped 0.47 percent, Mapletree Logistics Trust sank 0.51 percent, Oversea-Chinese Banking Corporation lost 0.34 percent, SATS surrendered 0.95 percent, SembCorp Industries tumbled 0.96 percent, Singapore Airlines tanked 1.09 percent, Singapore Exchange eased 0.21 percent, Singapore Technologies Engineering gained 0.79 percent, SingTel declined 0.78 percent, <a href=\"https://laohu8.com/S/UBNK\">United</a> Overseas Bank retreated 0.75 percent, Wilmar International plunged 1.14 percent, Yangzijiang Shipbuilding added 0.80 percent and Keppel Corp, Genting Singapore, CapitaLand, CapitaLand Integrated Commercial Trust, Thai Beverage and Singapore Press Holdings were unchanged.</p><p><blockquote>活跃股中，腾飞房地产投资信托下跌0.32%，而<a href=\"https://laohu8.com/S/CHCO\">城市</a>Developments上涨0.28%，Comfort DelGro和DBS Group均下跌0.62%，Dairy Farm International暴跌1.17%，Jardine Cycle上涨1.02%，Jardine Matheson上涨1.16%，丰树商业信托下跌0.47%，丰树物流信托下跌0.51%，华侨银行下跌0.34%，SATS退保0.95%，胜科工业下跌0.96%，新加坡航空下跌1.09%，新加坡交易所下跌0.21%，新加坡技术工程上涨0.79%，新加坡电信下跌0.78%，<a href=\"https://laohu8.com/S/UBNK\">团结的</a>海外银行下跌0.75%，丰益国际下跌1.14%，扬子江船业上涨0.80%，吉宝企业、云顶新加坡、凯德置地、凯德综合商业信托、泰国饮料和新加坡报业控股持平。</blockquote></p><p> The lead from Wall Street is broadly negative as the major averages opened slightly lower on Wednesday but saw the losses accelerate as the day progressed to finish solidly under water.</p><p><blockquote>华尔街的领先优势普遍为负面，主要股指周三开盘小幅走低，但随着当天的进展，跌幅加速，最终在水下收盘。</blockquote></p><p> The Dow tumbled 240.04 points or 0.66 percent to finish at 36,079.94, while the NASDAQ plunged 263.84 points or 1.66 percent to close at 15,622.71 and the S&amp;P 500 sank 38.54 points or 0.82 percent to end at 4,646.71.</p><p><blockquote>道琼斯指数下跌240.04点，跌幅0.66%，收于36,079.94点；纳斯达克下跌263.84点，跌幅1.66%，收于15,622.71点；标普500下跌38.54点，跌幅0.82%，收于4,646.71点。</blockquote></p><p> Concerns about inflation contributed to the weakness on Wall Street after the Labor Department released a report showing consumer prices increased by more than expected in October, lifting the annual rate of price growth to its highest level in over thirty years.</p><p><blockquote>美国劳工部发布报告显示，10月份消费者价格涨幅超出预期，将物价年增长率提升至三十多年来的最高水平，对通胀的担忧导致华尔街疲软。</blockquote></p><p> The acceleration in the rate of consumer price inflation raised concerns about the outlook for interest rates even though the Federal Reserve has signaled it will not be in a hurry to begin raising rates.</p><p><blockquote>尽管美联储已表示不会急于开始加息，但消费者价格通胀率的加速引发了人们对利率前景的担忧。</blockquote></p><p> Also, a separate report from the Labor Department showed another modest decrease in first-time claims for U.S. unemployment benefits last week.</p><p><blockquote>此外，劳工部的另一份报告显示，上周美国首次申请失业救济人数再次小幅下降。</blockquote></p><p> Crude oil prices declined sharply on Wednesday, snapping a three-day winning streak after data showed an increase in U.S. crude stockpiles last week. <a href=\"https://laohu8.com/S/WSTC\">West</a> Texas Intermediate Crude oil futures for December ended down by $2.81 or 3.3 percent at $81.34 a barrel.</p><p><blockquote>在数据显示上周美国原油库存增加后，原油价格周三大幅下跌，结束了连续三天的上涨。<a href=\"https://laohu8.com/S/WSTC\">西方</a>德州中质原油12月期货收跌2.81美元或3.3%，报每桶81.34美元。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.nasdaq.com/articles/continued-consolidation-called-for-singapore-shares\">RTTNews</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.nasdaq.com/articles/continued-consolidation-called-for-singapore-shares","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1163617251","content_text":"(RTTNews) - The Singapore stock market has finished lower in two straight sessions, dropping more than 30 points or 1 percent along the way. The Straits Times Index now sits just above the 3,230-point plateau and it may extend its losses on Thursday.\nThe global forecast for the Asian markets suggests consolidation on inflation concerns and a drop in crude oil prices. The European markets were up and the U.S. bourses were down and the Asian markets figure to follow the latter lead.\nThe STI finished modestly lower on Wednesday following losses from the financial shares, property stocks and industrial issues.\nFor the day, the index shed 12.10 points or 0.37 percent to finish at 3,231.32 after trading between 3,218.31 and 3,246.00. Volume was 2.03 billion shares worth 1.05 billion Singapore dollars. There were 256 decliners and 204 gainers.\nAmong the actives, Ascendas REIT fell 0.32 percent, while City Developments rose 0.28 percent, Comfort DelGro and DBS Group both skidded 0.62 percent, Dairy Farm International plummeted 1.17 percent, Jardine Cycle advanced 1.02 percent, Jardine Matheson climbed 1.16 percent, Mapletree Commercial Trust dropped 0.47 percent, Mapletree Logistics Trust sank 0.51 percent, Oversea-Chinese Banking Corporation lost 0.34 percent, SATS surrendered 0.95 percent, SembCorp Industries tumbled 0.96 percent, Singapore Airlines tanked 1.09 percent, Singapore Exchange eased 0.21 percent, Singapore Technologies Engineering gained 0.79 percent, SingTel declined 0.78 percent, United Overseas Bank retreated 0.75 percent, Wilmar International plunged 1.14 percent, Yangzijiang Shipbuilding added 0.80 percent and Keppel Corp, Genting Singapore, CapitaLand, CapitaLand Integrated Commercial Trust, Thai Beverage and Singapore Press Holdings were unchanged.\nThe lead from Wall Street is broadly negative as the major averages opened slightly lower on Wednesday but saw the losses accelerate as the day progressed to finish solidly under water.\nThe Dow tumbled 240.04 points or 0.66 percent to finish at 36,079.94, while the NASDAQ plunged 263.84 points or 1.66 percent to close at 15,622.71 and the S&P 500 sank 38.54 points or 0.82 percent to end at 4,646.71.\nConcerns about inflation contributed to the weakness on Wall Street after the Labor Department released a report showing consumer prices increased by more than expected in October, lifting the annual rate of price growth to its highest level in over thirty years.\nThe acceleration in the rate of consumer price inflation raised concerns about the outlook for interest rates even though the Federal Reserve has signaled it will not be in a hurry to begin raising rates.\nAlso, a separate report from the Labor Department showed another modest decrease in first-time claims for U.S. unemployment benefits last week.\nCrude oil prices declined sharply on Wednesday, snapping a three-day winning streak after data showed an increase in U.S. crude stockpiles last week. West Texas Intermediate Crude oil futures for December ended down by $2.81 or 3.3 percent at $81.34 a barrel.","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":1826,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":873789420,"gmtCreate":1636987209261,"gmtModify":1636987209401,"author":{"id":"3574933488250733","authorId":"3574933488250733","name":"DoubleClick","avatar":"https://static.tigerbbs.com/91c1a51c4f84aa921e0b29d4e1b8f7e1","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574933488250733","idStr":"3574933488250733"},"themes":[],"htmlText":"Here for the coins!","listText":"Here for the coins!","text":"Here for the coins!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/873789420","repostId":"873287761","repostType":1,"repost":{"id":873287761,"gmtCreate":1636948480350,"gmtModify":1636957657847,"author":{"id":"3527667583497005","authorId":"3527667583497005","name":"期权异动观察","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3527667583497005","idStr":"3527667583497005"},"themes":[],"title":"11.15期权异动观察，AMD反复异动","htmlText":"<a target=\"_blank\" href=\"https://laohu8.com/S/ACB\">$奥罗拉大麻公司(ACB)$</a>&nbsp;在<a target=\"_blank\" href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a> 的带动下，周五大麻股出现了集体异动，ACB公司评级获得了部分评级机构上调，后续走势看大麻bank整体走势。坎托菲茨杰拉德公司：维持Aurora Cannabis Inc(ACB.US)中性评级, 目标价由9.60美元调整至10.75美元。 <a target=\"_blank\" href=\"https://laohu8.com/S/AMD\">$AMD(AMD)$</a> 最近股价频繁异动，消息面趋于平静，股价依然处于强势状态。 <a target=\"_blank\" href=\"https://laohu8.com/S/ATVI\">$动视暴雪(ATVI)$</a>财报不及预期暴跌之后，最近走稳开始向上拉升， 消息面平静。 <a target=\"_blank\" href=\"https://laohu8.com/S/TTD\">$Trade Desk Inc.(TTD)$</a>最近也是二次异动，该股依然处于强势上攻，奥本海默在11.9日将公司的目标价从95美元上调至100美元。 <a target=\"_blank\" href=\"https://laohu8.com/S/TSLA\">$特斯拉(TSLA)$</a> 上周下跌15%，马斯克持续减持股份，短期走势看震荡，目测这个月马斯克就可以将手里的股份减持完毕。 <a href=\"https://laohu8.com/TW/854739948\" target=\"_blank\">目前模拟账户也已经上线了期权交易功能，</a>","listText":"<a target=\"_blank\" href=\"https://laohu8.com/S/ACB\">$奥罗拉大麻公司(ACB)$</a>&nbsp;在<a target=\"_blank\" href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a> 的带动下，周五大麻股出现了集体异动，ACB公司评级获得了部分评级机构上调，后续走势看大麻bank整体走势。坎托菲茨杰拉德公司：维持Aurora Cannabis Inc(ACB.US)中性评级, 目标价由9.60美元调整至10.75美元。 <a target=\"_blank\" href=\"https://laohu8.com/S/AMD\">$AMD(AMD)$</a> 最近股价频繁异动，消息面趋于平静，股价依然处于强势状态。 <a target=\"_blank\" href=\"https://laohu8.com/S/ATVI\">$动视暴雪(ATVI)$</a>财报不及预期暴跌之后，最近走稳开始向上拉升， 消息面平静。 <a target=\"_blank\" href=\"https://laohu8.com/S/TTD\">$Trade Desk Inc.(TTD)$</a>最近也是二次异动，该股依然处于强势上攻，奥本海默在11.9日将公司的目标价从95美元上调至100美元。 <a target=\"_blank\" href=\"https://laohu8.com/S/TSLA\">$特斯拉(TSLA)$</a> 上周下跌15%，马斯克持续减持股份，短期走势看震荡，目测这个月马斯克就可以将手里的股份减持完毕。 <a href=\"https://laohu8.com/TW/854739948\" target=\"_blank\">目前模拟账户也已经上线了期权交易功能，</a>","text":"$奥罗拉大麻公司(ACB)$ 在$Sundial Growers Inc.(SNDL)$ 的带动下，周五大麻股出现了集体异动，ACB公司评级获得了部分评级机构上调，后续走势看大麻bank整体走势。坎托菲茨杰拉德公司：维持Aurora Cannabis Inc(ACB.US)中性评级, 目标价由9.60美元调整至10.75美元。 $AMD(AMD)$ 最近股价频繁异动，消息面趋于平静，股价依然处于强势状态。 $动视暴雪(ATVI)$财报不及预期暴跌之后，最近走稳开始向上拉升， 消息面平静。 $Trade Desk Inc.(TTD)$最近也是二次异动，该股依然处于强势上攻，奥本海默在11.9日将公司的目标价从95美元上调至100美元。 $特斯拉(TSLA)$ 上周下跌15%，马斯克持续减持股份，短期走势看震荡，目测这个月马斯克就可以将手里的股份减持完毕。 目前模拟账户也已经上线了期权交易功能，","images":[{"img":"https://static.tigerbbs.com/913d99ad732154469e49fa9467361f77","width":"799","height":"698"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/873287761","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1229,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":848639075,"gmtCreate":1635993150614,"gmtModify":1635993150735,"author":{"id":"3574933488250733","authorId":"3574933488250733","name":"DoubleClick","avatar":"https://static.tigerbbs.com/91c1a51c4f84aa921e0b29d4e1b8f7e1","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574933488250733","idStr":"3574933488250733"},"themes":[],"htmlText":"Happy Diwali Everyone!&nbsp;","listText":"Happy Diwali Everyone!&nbsp;","text":"Happy Diwali Everyone!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/848639075","isVote":1,"tweetType":1,"viewCount":1612,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":849880046,"gmtCreate":1635741983209,"gmtModify":1635741983209,"author":{"id":"3574933488250733","authorId":"3574933488250733","name":"DoubleClick","avatar":"https://static.tigerbbs.com/91c1a51c4f84aa921e0b29d4e1b8f7e1","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574933488250733","idStr":"3574933488250733"},"themes":[],"htmlText":"Nice!","listText":"Nice!","text":"Nice!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/849880046","repostId":"1164035523","repostType":2,"repost":{"id":"1164035523","kind":"news","pubTimestamp":1635736469,"share":"https://www.laohu8.com/m/news/1164035523?lang=zh_CN&edition=full","pubTime":"2021-11-01 11:14","market":"us","language":"en","title":"2 Growth Stocks That Could Deliver 1,000% Returns<blockquote>2只可带来1,000%回报的成长型股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1164035523","media":"Motley Fool","summary":"Thanks to the ongoing innovation revolutions in both the tech and healthcare sectors, shareholders h","content":"<p>Thanks to the ongoing innovation revolutions in both the tech and healthcare sectors, shareholders have been enjoying historic returns on capital over the past decade. For example, the central nervous system disorder drug specialist&nbsp;<b>Axsome Therapeutics</b>, the cancer specialist&nbsp;<b>Exelixis</b>, and the electric car pioneer&nbsp;<b>Tesla</b>&nbsp;have all delivered tenfold returns for investors who bought these names at their low points.</p><p><blockquote>由于科技和医疗保健领域持续的创新革命，股东在过去十年中一直享受着历史性的资本回报。例如，中枢神经系统疾病药物专家<b>轴体疗法</b>，癌症专家<b>Exelixis</b>，以及电动汽车先驱<b>特斯拉</b>都为在低点买入这些股票的投资者带来了十倍的回报。</blockquote></p><p> Which stocks might be the next Axsome, Exelixis, or Tesla from a growth standpoint? The cancer/rare disease specialist&nbsp;<b>Mereo BioPharma Group</b>(NASDAQ:MREO)and the diabetes-focused medical device company&nbsp;<b>Senseonics Holdings</b>(NYSEMKT:SENS)could both be gearing up for a monstrous run higher soon. In fact, these two low-priced&nbsp;healthcare stocks&nbsp;have a decent shot at generating 1,000%-plus returns for their shareholders within the next two to three years.</p><p><blockquote>从增长的角度来看，哪些股票可能成为下一个Axsome、Exelixis或特斯拉？癌症/罕见病专家<b>Mereo生物制药集团</b>（纳斯达克：MREO）和专注于糖尿病的医疗器械公司<b>Senseonics控股</b>(NYSEMKT：SENS)两者都可能很快就会为大幅走高做准备。事实上，这两只低价医疗保健股很有可能在未来两到三年内为股东带来1,000%以上的回报。</blockquote></p><p> Here's a brief overview on the risks and potential rewards associated with each of these promising growth vehicles.</p><p><blockquote>以下是与这些有前途的增长工具相关的风险和潜在回报的简要概述。</blockquote></p><p> <b>Mereo BioPharma: A bet on the future of immunotherapy</b></p><p><blockquote><b>Mereo BioPharma：押注免疫疗法的未来</b></blockquote></p><p> The London-based biopharma Mereo hasn't exactly set the world on fire since its American depository shares (ADS) made their debut on the Nasdaq stock exchange. Keeping with this theme, the biotech's ADSes have lost approximately 65% of their value since April 2019. This steady downward trend shouldn't scare away aggressive investors, however. Mereo's plunging share price, after all, is more about Mr. Market's well-known impatience with clinical-stage biotechs, rather than the company's underlying value proposition.</p><p><blockquote>自其美国存托股票(ADS)在纳斯达克证券交易所首次亮相以来，总部位于伦敦的生物制药公司Mereo并没有真正引起轰动。与这一主题保持一致，自2019年4月以来，该生物技术公司的ADSE已损失约65%的价值。然而，这种稳定的下降趋势不应吓跑激进的投资者。毕竟，Mereo股价暴跌更多的是市场先生对临床阶段生物技术众所周知的不耐烦，而不是该公司的潜在价值主张。</blockquote></p><p> What's the scoop? Mereo is a small-cap company with six assets under development for both cancer and rare diseases. However, the one drug candidate that could undoubtedly send the company's shares rocketing higher is the&nbsp;anti-TIGIT therapy&nbsp;known as etigilimab. Several major drug companies, such as&nbsp;<b>BeiGene</b>,<b>Bristol Myers Squibb</b>,<b>Merck</b>, and&nbsp;<b>Roche</b>, have anti-TIGIT therapies under development due to their potential to boost the efficacy and durability of cancer immunotherapy treatments in general. Mereo's etigilimab is currently in a combined phase 1/2 basket study to evaluate its utility as part of combination treament, along with Bristol's megablockbuster checkpoint inhibitor Opdivo, for a variety of solid tumors.</p><p><blockquote>有什么独家新闻？Mereo是一家小型公司，拥有六项正在开发的癌症和罕见疾病资产。然而，一种无疑可能推动该公司股价飙升的候选药物是名为etigilimab的抗TIGIT疗法。几大药企，如<b>百济神州</b>,<b>百时美施贵宝</b>,<b>默克</b>，和<b>罗氏</b>由于抗TIGIT疗法通常具有增强癌症免疫疗法的功效和持久性的潜力，因此正在开发抗TIGIT疗法。Mereo的etigilimab目前正在进行一项联合1/2期篮子研究，以评估其作为联合治疗的一部分，与Bristol的megablockbuster检查点抑制剂Opdivo一起用于多种实体瘤。</blockquote></p><p> As things stand now, Mereo's anti-TIGIT candidate is slated to yield top-line data from this basket trial in approximately 18-months from now. During this lengthy interval, however, the drugmaker ought to provide multiple updates on etigilimab's progress, which could turn out to be a series of major catalysts for its share price in the coming months. Another bit of good news is that Mereo's cash runway reportedly extends into 2024. That's key, because it means that the biotech shouldn't have to repeatly tap the public markets for capital over the next year and a half.</p><p><blockquote>就目前情况而言，Mereo的抗TIGIT候选药物预计将在大约18个月后从这项篮子试验中产生顶线数据。然而，在这段漫长的时间间隔内，该制药商应该提供有关etigilimab进展的多项最新信息，这可能会成为未来几个月其股价的一系列主要催化剂。另一个好消息是，据报道Mereo的现金跑道将延伸至2024年。这是关键，因为这意味着生物技术公司不应该在未来一年半内反复利用公开市场获取资本。</blockquote></p><p> What's the downside risk? Mereo's management team has been open about its desire to partner with larger biopharmas. Etigilimab, for its part, could spark either a high dollar licensing agreement or a full-on buyout within the next two years. So a lot is riding on this single experimental drug. Unfortunately, early stage cancer therapies fail more often than not in the clinic. As a failure in this case would weigh heavily on the biotech's share price, potential investors may want to keep any initial position on the small side.</p><p><blockquote>下行风险是什么？Mereo的管理团队一直公开表示希望与大型生物制药公司合作。就Etigilimab而言，它可能会在未来两年内引发高额许可协议或全面收购。所以很大程度上取决于这种单一的实验药物。不幸的是，早期癌症疗法在临床上经常失败。由于这种情况下的失败将严重影响生物技术公司的股价，潜在投资者可能希望将初始头寸保持在较小的水平。</blockquote></p><p> <b>Senseonic: A rising tide lifts all boats</b></p><p><blockquote><b>Senseonic：水涨船高</b></blockquote></p><p> Senseonics' stock is worth a look by ultra-aggressive investors due to its implantable continuous glucose monitoring (CGM) device franchise known as Eversense. The lowdown is that the CGM market has been growing by over 10%&nbsp;<i>per year</i>&nbsp;over the past five years, according to a report by Grand View Research. What's more, this space is forecast to grow by at least 10% per year over the next five years. That's definitely a favorable trend for a small-cap CGM player like Senseonics.</p><p><blockquote>Senseonics的股票值得超级激进的投资者关注，因为它拥有名为Eversense的植入式连续血糖监测(CGM)设备专营权。真相是CGM市场增长超过10%<i>每年</i>根据Grand View Research的一份报告，在过去五年中。更重要的是，该领域预计在未来五年内每年至少增长10%。对于像Senseonics这样的小型CGM参与者来说，这绝对是一个有利的趋势。</blockquote></p><p> So far, Senseonics has only captured a&nbsp;small sliver&nbsp;of this multi-billion dollar medical device market with its Eversense franchise. But the company is hoping to drastically improve its competitive positioning with a potential regulatory approval by the Food and Drug Administration (FDA) for its 180-day version of the Eversense CGM system. The medical device company&nbsp;submitteda regulatory application to the FDA for this proposed product over a year ago. So a decision could come any day now.</p><p><blockquote>到目前为止，Senseonics仅凭借其Eversense特许经营权占领了这个价值数十亿美元的医疗设备市场的一小部分。但该公司希望通过食品和药物管理局(FDA)对其180天版本的Eversense CGM系统的潜在监管批准来大幅提高其竞争地位。该医疗器械公司一年多前就该拟议产品向FDA提交了监管申请。所以现在随时都可能做出决定。</blockquote></p><p></p><p> Why does this FDA approval matter? Senseonics' internal projections have the company's top-line rising at a compound annual growth rate of over 70% over the next five years as a result of this key regulatory nod. The long and short of it is that the current 90-day Eversense CGM system isn't particularly competitive in the U.S. against the market-leading devices from&nbsp;<b>DexCom</b>&nbsp;and&nbsp;<b>Abbott Laboratories</b>, respectively. But this longer-lasting version of the device could cause sales to skyrocket in the coming years.</p><p><blockquote>为什么FDA的批准很重要？Senseonics的内部预测显示，由于这一关键的监管批准，该公司的营收在未来五年内将以超过70%的复合年增长率增长。总而言之，目前的90天Eversense CGM系统在美国与市场领先的设备相比并没有特别的竞争力<b>DexCom</b>和<b>雅培实验室</b>，分别。但这种更耐用的设备版本可能会在未来几年导致销量飙升。</blockquote></p><p> What's the risk? Senseonics is competing in a jam-packed space against a number of well-capitalized medical-device giants. So there is a chance that this long-awaited FDA approval won't spark a parabolic rise in sales. That's not a knock against Senseonics' CGM system, but rather the harsh reality of competing against healthcare companies with vastly superior resources. Investors shouldn't ignore this potential risk factor.</p><p><blockquote>有什么风险？Senseonics正在拥挤的空间中与许多资本雄厚的医疗设备巨头竞争。因此，这一期待已久的FDA批准有可能不会引发销售额的抛物线增长。这并不是对Senseonics CGM系统的打击，而是与拥有极其优越资源的医疗保健公司竞争的残酷现实。投资者不应忽视这一潜在的风险因素。</blockquote></p><p> All told, Senseonics could be on the verge of a game-changing regulatory event that might prove to be a key inflection point for the company's CGM franchise. If true, this medical device company's stock should turn out to be a downright bargain at these levels.</p><p><blockquote>总而言之，Senseonics可能正处于改变游戏规则的监管事件的边缘，这可能会成为该公司CGM特许经营权的一个关键转折点。如果属实，这家医疗器械公司的股票在这些水平上应该会非常便宜。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Growth Stocks That Could Deliver 1,000% Returns<blockquote>2只可带来1,000%回报的成长型股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Growth Stocks That Could Deliver 1,000% Returns<blockquote>2只可带来1,000%回报的成长型股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-11-01 11:14</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Thanks to the ongoing innovation revolutions in both the tech and healthcare sectors, shareholders have been enjoying historic returns on capital over the past decade. For example, the central nervous system disorder drug specialist&nbsp;<b>Axsome Therapeutics</b>, the cancer specialist&nbsp;<b>Exelixis</b>, and the electric car pioneer&nbsp;<b>Tesla</b>&nbsp;have all delivered tenfold returns for investors who bought these names at their low points.</p><p><blockquote>由于科技和医疗保健领域持续的创新革命，股东在过去十年中一直享受着历史性的资本回报。例如，中枢神经系统疾病药物专家<b>轴体疗法</b>，癌症专家<b>Exelixis</b>，以及电动汽车先驱<b>特斯拉</b>都为在低点买入这些股票的投资者带来了十倍的回报。</blockquote></p><p> Which stocks might be the next Axsome, Exelixis, or Tesla from a growth standpoint? The cancer/rare disease specialist&nbsp;<b>Mereo BioPharma Group</b>(NASDAQ:MREO)and the diabetes-focused medical device company&nbsp;<b>Senseonics Holdings</b>(NYSEMKT:SENS)could both be gearing up for a monstrous run higher soon. In fact, these two low-priced&nbsp;healthcare stocks&nbsp;have a decent shot at generating 1,000%-plus returns for their shareholders within the next two to three years.</p><p><blockquote>从增长的角度来看，哪些股票可能成为下一个Axsome、Exelixis或特斯拉？癌症/罕见病专家<b>Mereo生物制药集团</b>（纳斯达克：MREO）和专注于糖尿病的医疗器械公司<b>Senseonics控股</b>(NYSEMKT：SENS)两者都可能很快就会为大幅走高做准备。事实上，这两只低价医疗保健股很有可能在未来两到三年内为股东带来1,000%以上的回报。</blockquote></p><p> Here's a brief overview on the risks and potential rewards associated with each of these promising growth vehicles.</p><p><blockquote>以下是与这些有前途的增长工具相关的风险和潜在回报的简要概述。</blockquote></p><p> <b>Mereo BioPharma: A bet on the future of immunotherapy</b></p><p><blockquote><b>Mereo BioPharma：押注免疫疗法的未来</b></blockquote></p><p> The London-based biopharma Mereo hasn't exactly set the world on fire since its American depository shares (ADS) made their debut on the Nasdaq stock exchange. Keeping with this theme, the biotech's ADSes have lost approximately 65% of their value since April 2019. This steady downward trend shouldn't scare away aggressive investors, however. Mereo's plunging share price, after all, is more about Mr. Market's well-known impatience with clinical-stage biotechs, rather than the company's underlying value proposition.</p><p><blockquote>自其美国存托股票(ADS)在纳斯达克证券交易所首次亮相以来，总部位于伦敦的生物制药公司Mereo并没有真正引起轰动。与这一主题保持一致，自2019年4月以来，该生物技术公司的ADSE已损失约65%的价值。然而，这种稳定的下降趋势不应吓跑激进的投资者。毕竟，Mereo股价暴跌更多的是市场先生对临床阶段生物技术众所周知的不耐烦，而不是该公司的潜在价值主张。</blockquote></p><p> What's the scoop? Mereo is a small-cap company with six assets under development for both cancer and rare diseases. However, the one drug candidate that could undoubtedly send the company's shares rocketing higher is the&nbsp;anti-TIGIT therapy&nbsp;known as etigilimab. Several major drug companies, such as&nbsp;<b>BeiGene</b>,<b>Bristol Myers Squibb</b>,<b>Merck</b>, and&nbsp;<b>Roche</b>, have anti-TIGIT therapies under development due to their potential to boost the efficacy and durability of cancer immunotherapy treatments in general. Mereo's etigilimab is currently in a combined phase 1/2 basket study to evaluate its utility as part of combination treament, along with Bristol's megablockbuster checkpoint inhibitor Opdivo, for a variety of solid tumors.</p><p><blockquote>有什么独家新闻？Mereo是一家小型公司，拥有六项正在开发的癌症和罕见疾病资产。然而，一种无疑可能推动该公司股价飙升的候选药物是名为etigilimab的抗TIGIT疗法。几大药企，如<b>百济神州</b>,<b>百时美施贵宝</b>,<b>默克</b>，和<b>罗氏</b>由于抗TIGIT疗法通常具有增强癌症免疫疗法的功效和持久性的潜力，因此正在开发抗TIGIT疗法。Mereo的etigilimab目前正在进行一项联合1/2期篮子研究，以评估其作为联合治疗的一部分，与Bristol的megablockbuster检查点抑制剂Opdivo一起用于多种实体瘤。</blockquote></p><p> As things stand now, Mereo's anti-TIGIT candidate is slated to yield top-line data from this basket trial in approximately 18-months from now. During this lengthy interval, however, the drugmaker ought to provide multiple updates on etigilimab's progress, which could turn out to be a series of major catalysts for its share price in the coming months. Another bit of good news is that Mereo's cash runway reportedly extends into 2024. That's key, because it means that the biotech shouldn't have to repeatly tap the public markets for capital over the next year and a half.</p><p><blockquote>就目前情况而言，Mereo的抗TIGIT候选药物预计将在大约18个月后从这项篮子试验中产生顶线数据。然而，在这段漫长的时间间隔内，该制药商应该提供有关etigilimab进展的多项最新信息，这可能会成为未来几个月其股价的一系列主要催化剂。另一个好消息是，据报道Mereo的现金跑道将延伸至2024年。这是关键，因为这意味着生物技术公司不应该在未来一年半内反复利用公开市场获取资本。</blockquote></p><p> What's the downside risk? Mereo's management team has been open about its desire to partner with larger biopharmas. Etigilimab, for its part, could spark either a high dollar licensing agreement or a full-on buyout within the next two years. So a lot is riding on this single experimental drug. Unfortunately, early stage cancer therapies fail more often than not in the clinic. As a failure in this case would weigh heavily on the biotech's share price, potential investors may want to keep any initial position on the small side.</p><p><blockquote>下行风险是什么？Mereo的管理团队一直公开表示希望与大型生物制药公司合作。就Etigilimab而言，它可能会在未来两年内引发高额许可协议或全面收购。所以很大程度上取决于这种单一的实验药物。不幸的是，早期癌症疗法在临床上经常失败。由于这种情况下的失败将严重影响生物技术公司的股价，潜在投资者可能希望将初始头寸保持在较小的水平。</blockquote></p><p> <b>Senseonic: A rising tide lifts all boats</b></p><p><blockquote><b>Senseonic：水涨船高</b></blockquote></p><p> Senseonics' stock is worth a look by ultra-aggressive investors due to its implantable continuous glucose monitoring (CGM) device franchise known as Eversense. The lowdown is that the CGM market has been growing by over 10%&nbsp;<i>per year</i>&nbsp;over the past five years, according to a report by Grand View Research. What's more, this space is forecast to grow by at least 10% per year over the next five years. That's definitely a favorable trend for a small-cap CGM player like Senseonics.</p><p><blockquote>Senseonics的股票值得超级激进的投资者关注，因为它拥有名为Eversense的植入式连续血糖监测(CGM)设备专营权。真相是CGM市场增长超过10%<i>每年</i>根据Grand View Research的一份报告，在过去五年中。更重要的是，该领域预计在未来五年内每年至少增长10%。对于像Senseonics这样的小型CGM参与者来说，这绝对是一个有利的趋势。</blockquote></p><p> So far, Senseonics has only captured a&nbsp;small sliver&nbsp;of this multi-billion dollar medical device market with its Eversense franchise. But the company is hoping to drastically improve its competitive positioning with a potential regulatory approval by the Food and Drug Administration (FDA) for its 180-day version of the Eversense CGM system. The medical device company&nbsp;submitteda regulatory application to the FDA for this proposed product over a year ago. So a decision could come any day now.</p><p><blockquote>到目前为止，Senseonics仅凭借其Eversense特许经营权占领了这个价值数十亿美元的医疗设备市场的一小部分。但该公司希望通过食品和药物管理局(FDA)对其180天版本的Eversense CGM系统的潜在监管批准来大幅提高其竞争地位。该医疗器械公司一年多前就该拟议产品向FDA提交了监管申请。所以现在随时都可能做出决定。</blockquote></p><p></p><p> Why does this FDA approval matter? Senseonics' internal projections have the company's top-line rising at a compound annual growth rate of over 70% over the next five years as a result of this key regulatory nod. The long and short of it is that the current 90-day Eversense CGM system isn't particularly competitive in the U.S. against the market-leading devices from&nbsp;<b>DexCom</b>&nbsp;and&nbsp;<b>Abbott Laboratories</b>, respectively. But this longer-lasting version of the device could cause sales to skyrocket in the coming years.</p><p><blockquote>为什么FDA的批准很重要？Senseonics的内部预测显示，由于这一关键的监管批准，该公司的营收在未来五年内将以超过70%的复合年增长率增长。总而言之，目前的90天Eversense CGM系统在美国与市场领先的设备相比并没有特别的竞争力<b>DexCom</b>和<b>雅培实验室</b>，分别。但这种更耐用的设备版本可能会在未来几年导致销量飙升。</blockquote></p><p> What's the risk? Senseonics is competing in a jam-packed space against a number of well-capitalized medical-device giants. So there is a chance that this long-awaited FDA approval won't spark a parabolic rise in sales. That's not a knock against Senseonics' CGM system, but rather the harsh reality of competing against healthcare companies with vastly superior resources. Investors shouldn't ignore this potential risk factor.</p><p><blockquote>有什么风险？Senseonics正在拥挤的空间中与许多资本雄厚的医疗设备巨头竞争。因此，这一期待已久的FDA批准有可能不会引发销售额的抛物线增长。这并不是对Senseonics CGM系统的打击，而是与拥有极其优越资源的医疗保健公司竞争的残酷现实。投资者不应忽视这一潜在的风险因素。</blockquote></p><p> All told, Senseonics could be on the verge of a game-changing regulatory event that might prove to be a key inflection point for the company's CGM franchise. If true, this medical device company's stock should turn out to be a downright bargain at these levels.</p><p><blockquote>总而言之，Senseonics可能正处于改变游戏规则的监管事件的边缘，这可能会成为该公司CGM特许经营权的一个关键转折点。如果属实，这家医疗器械公司的股票在这些水平上应该会非常便宜。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/10/31/2-growth-stocks-that-could-deliver-1000-returns/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SENS":"Senseonics Holdings,Inc.","MREO":"Mereo Biopharma Group Plc"},"source_url":"https://www.fool.com/investing/2021/10/31/2-growth-stocks-that-could-deliver-1000-returns/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164035523","content_text":"Thanks to the ongoing innovation revolutions in both the tech and healthcare sectors, shareholders have been enjoying historic returns on capital over the past decade. For example, the central nervous system disorder drug specialist Axsome Therapeutics, the cancer specialist Exelixis, and the electric car pioneer Tesla have all delivered tenfold returns for investors who bought these names at their low points.\nWhich stocks might be the next Axsome, Exelixis, or Tesla from a growth standpoint? The cancer/rare disease specialist Mereo BioPharma Group(NASDAQ:MREO)and the diabetes-focused medical device company Senseonics Holdings(NYSEMKT:SENS)could both be gearing up for a monstrous run higher soon. In fact, these two low-priced healthcare stocks have a decent shot at generating 1,000%-plus returns for their shareholders within the next two to three years.\nHere's a brief overview on the risks and potential rewards associated with each of these promising growth vehicles.\nMereo BioPharma: A bet on the future of immunotherapy\nThe London-based biopharma Mereo hasn't exactly set the world on fire since its American depository shares (ADS) made their debut on the Nasdaq stock exchange. Keeping with this theme, the biotech's ADSes have lost approximately 65% of their value since April 2019. This steady downward trend shouldn't scare away aggressive investors, however. Mereo's plunging share price, after all, is more about Mr. Market's well-known impatience with clinical-stage biotechs, rather than the company's underlying value proposition.\nWhat's the scoop? Mereo is a small-cap company with six assets under development for both cancer and rare diseases. However, the one drug candidate that could undoubtedly send the company's shares rocketing higher is the anti-TIGIT therapy known as etigilimab. Several major drug companies, such as BeiGene,Bristol Myers Squibb,Merck, and Roche, have anti-TIGIT therapies under development due to their potential to boost the efficacy and durability of cancer immunotherapy treatments in general. Mereo's etigilimab is currently in a combined phase 1/2 basket study to evaluate its utility as part of combination treament, along with Bristol's megablockbuster checkpoint inhibitor Opdivo, for a variety of solid tumors.\nAs things stand now, Mereo's anti-TIGIT candidate is slated to yield top-line data from this basket trial in approximately 18-months from now. During this lengthy interval, however, the drugmaker ought to provide multiple updates on etigilimab's progress, which could turn out to be a series of major catalysts for its share price in the coming months. Another bit of good news is that Mereo's cash runway reportedly extends into 2024. That's key, because it means that the biotech shouldn't have to repeatly tap the public markets for capital over the next year and a half.\nWhat's the downside risk? Mereo's management team has been open about its desire to partner with larger biopharmas. Etigilimab, for its part, could spark either a high dollar licensing agreement or a full-on buyout within the next two years. So a lot is riding on this single experimental drug. Unfortunately, early stage cancer therapies fail more often than not in the clinic. As a failure in this case would weigh heavily on the biotech's share price, potential investors may want to keep any initial position on the small side.\nSenseonic: A rising tide lifts all boats\nSenseonics' stock is worth a look by ultra-aggressive investors due to its implantable continuous glucose monitoring (CGM) device franchise known as Eversense. The lowdown is that the CGM market has been growing by over 10% per year over the past five years, according to a report by Grand View Research. What's more, this space is forecast to grow by at least 10% per year over the next five years. That's definitely a favorable trend for a small-cap CGM player like Senseonics.\nSo far, Senseonics has only captured a small sliver of this multi-billion dollar medical device market with its Eversense franchise. But the company is hoping to drastically improve its competitive positioning with a potential regulatory approval by the Food and Drug Administration (FDA) for its 180-day version of the Eversense CGM system. The medical device company submitteda regulatory application to the FDA for this proposed product over a year ago. So a decision could come any day now.\nWhy does this FDA approval matter? Senseonics' internal projections have the company's top-line rising at a compound annual growth rate of over 70% over the next five years as a result of this key regulatory nod. The long and short of it is that the current 90-day Eversense CGM system isn't particularly competitive in the U.S. against the market-leading devices from DexCom and Abbott Laboratories, respectively. But this longer-lasting version of the device could cause sales to skyrocket in the coming years.\nWhat's the risk? Senseonics is competing in a jam-packed space against a number of well-capitalized medical-device giants. So there is a chance that this long-awaited FDA approval won't spark a parabolic rise in sales. That's not a knock against Senseonics' CGM system, but rather the harsh reality of competing against healthcare companies with vastly superior resources. Investors shouldn't ignore this potential risk factor.\nAll told, Senseonics could be on the verge of a game-changing regulatory event that might prove to be a key inflection point for the company's CGM franchise. If true, this medical device company's stock should turn out to be a downright bargain at these levels.","news_type":1,"symbols_score_info":{"SENS":0.9,"MREO":0.9}},"isVote":1,"tweetType":1,"viewCount":1972,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":164993620,"gmtCreate":1624164144060,"gmtModify":1634009935589,"author":{"id":"3574933488250733","authorId":"3574933488250733","name":"DoubleClick","avatar":"https://static.tigerbbs.com/91c1a51c4f84aa921e0b29d4e1b8f7e1","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574933488250733","idStr":"3574933488250733"},"themes":[],"htmlText":"Latest","listText":"Latest","text":"Latest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/164993620","repostId":"1126454279","repostType":2,"isVote":1,"tweetType":1,"viewCount":146,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":874477757,"gmtCreate":1637818653179,"gmtModify":1637818653328,"author":{"id":"3574933488250733","authorId":"3574933488250733","name":"DoubleClick","avatar":"https://static.tigerbbs.com/91c1a51c4f84aa921e0b29d4e1b8f7e1","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574933488250733","idStr":"3574933488250733"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/IQ\">$iQiyi Inc.(IQ)$</a> 是我的第一次","listText":"<a href=\"https://laohu8.com/S/IQ\">$iQiyi Inc.(IQ)$</a> 是我的第一次","text":"$iQiyi Inc.(IQ)$ 是我的第一次","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/874477757","repostId":"875266611","repostType":1,"repost":{"id":875266611,"gmtCreate":1637659026330,"gmtModify":1637929617182,"author":{"id":"36984908995200","authorId":"36984908995200","name":"小虎活动","avatar":"https://static.tigerbbs.com/9e396d03155923b283948d2dec9191f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"36984908995200","idStr":"36984908995200"},"themes":[],"title":"【感恩回馈】说说你和老虎的第一次","htmlText":"感恩节马上要到了，小虎提醒：感恩节周四(11月25日)美股休市哦！感恩节翌日(26日)美股提前3小时收盘~ 为了回馈广大虎友们的支持与陪伴，小虎君为大家准备了一些小礼物，参与即可获赠66虎币，如果你愿意多聊2句，还有机会获得小虎全套盲盒。 不知不觉，老虎已经成立7年了， 在过去年的7年，我们认识了很多新老朋友 可曾记得你是何时加入老虎的？ 又是缘何来到这里？ 【参与方式】 本帖留言说出 「你和老虎的第一次」 你发布的第一个帖子是什么？ 你关注的第一个好友是谁？ 你关注/交易的第一只股票是什么？ 【活动奖励】 凡是参与晒单的虎友均可获得66虎币，除此之外，还有机会获得以下奖励： 知己奖：我们会选取“第一条帖子”发帖时间最早的虎友赠予1套小虎盲盒手办（5个） 人气奖：我们会选取评论获赞量最高的3位虎友，随机赠予小虎盲盒手办1个 优质奖：我们会随机选取评论优质有趣的虎友，随机赠予小虎盲盒手办1个 【活动时间】： 2021年11月23日-11月29日 【特别说明】 水贴，重复内容，广告，恶意营销等属于无效内容； 文章需原创并首发于老虎，并且版权归老虎社区所有； 本次活动中用户所提到的标的，仅供参考，不构成投资建议，据此操作，风险自负； 活动最终解释权归老虎社区所有； 若对本次活动有不解之处，可在此贴留言，或微信虎妞（微信号：itiger2014）咨询。 欢迎大家在下贴评论区留言说说「你和老虎的第一次」，你发布的第一个帖子是什么？你关注的第一个好友是谁？你关注/交易的第一只股票是什么？参与即可获赠66虎币，如果你愿意多聊2句，还有机会获得小虎全套盲盒。","listText":"感恩节马上要到了，小虎提醒：感恩节周四(11月25日)美股休市哦！感恩节翌日(26日)美股提前3小时收盘~ 为了回馈广大虎友们的支持与陪伴，小虎君为大家准备了一些小礼物，参与即可获赠66虎币，如果你愿意多聊2句，还有机会获得小虎全套盲盒。 不知不觉，老虎已经成立7年了， 在过去年的7年，我们认识了很多新老朋友 可曾记得你是何时加入老虎的？ 又是缘何来到这里？ 【参与方式】 本帖留言说出 「你和老虎的第一次」 你发布的第一个帖子是什么？ 你关注的第一个好友是谁？ 你关注/交易的第一只股票是什么？ 【活动奖励】 凡是参与晒单的虎友均可获得66虎币，除此之外，还有机会获得以下奖励： 知己奖：我们会选取“第一条帖子”发帖时间最早的虎友赠予1套小虎盲盒手办（5个） 人气奖：我们会选取评论获赞量最高的3位虎友，随机赠予小虎盲盒手办1个 优质奖：我们会随机选取评论优质有趣的虎友，随机赠予小虎盲盒手办1个 【活动时间】： 2021年11月23日-11月29日 【特别说明】 水贴，重复内容，广告，恶意营销等属于无效内容； 文章需原创并首发于老虎，并且版权归老虎社区所有； 本次活动中用户所提到的标的，仅供参考，不构成投资建议，据此操作，风险自负； 活动最终解释权归老虎社区所有； 若对本次活动有不解之处，可在此贴留言，或微信虎妞（微信号：itiger2014）咨询。 欢迎大家在下贴评论区留言说说「你和老虎的第一次」，你发布的第一个帖子是什么？你关注的第一个好友是谁？你关注/交易的第一只股票是什么？参与即可获赠66虎币，如果你愿意多聊2句，还有机会获得小虎全套盲盒。","text":"感恩节马上要到了，小虎提醒：感恩节周四(11月25日)美股休市哦！感恩节翌日(26日)美股提前3小时收盘~ 为了回馈广大虎友们的支持与陪伴，小虎君为大家准备了一些小礼物，参与即可获赠66虎币，如果你愿意多聊2句，还有机会获得小虎全套盲盒。 不知不觉，老虎已经成立7年了， 在过去年的7年，我们认识了很多新老朋友 可曾记得你是何时加入老虎的？ 又是缘何来到这里？ 【参与方式】 本帖留言说出 「你和老虎的第一次」 你发布的第一个帖子是什么？ 你关注的第一个好友是谁？ 你关注/交易的第一只股票是什么？ 【活动奖励】 凡是参与晒单的虎友均可获得66虎币，除此之外，还有机会获得以下奖励： 知己奖：我们会选取“第一条帖子”发帖时间最早的虎友赠予1套小虎盲盒手办（5个） 人气奖：我们会选取评论获赞量最高的3位虎友，随机赠予小虎盲盒手办1个 优质奖：我们会随机选取评论优质有趣的虎友，随机赠予小虎盲盒手办1个 【活动时间】： 2021年11月23日-11月29日 【特别说明】 水贴，重复内容，广告，恶意营销等属于无效内容； 文章需原创并首发于老虎，并且版权归老虎社区所有； 本次活动中用户所提到的标的，仅供参考，不构成投资建议，据此操作，风险自负； 活动最终解释权归老虎社区所有； 若对本次活动有不解之处，可在此贴留言，或微信虎妞（微信号：itiger2014）咨询。 欢迎大家在下贴评论区留言说说「你和老虎的第一次」，你发布的第一个帖子是什么？你关注的第一个好友是谁？你关注/交易的第一只股票是什么？参与即可获赠66虎币，如果你愿意多聊2句，还有机会获得小虎全套盲盒。","images":[{"img":"https://static.tigerbbs.com/b56d1364489aaafc34e363d2b2b842a8","width":"1462","height":"818"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875266611","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":2288,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":874434632,"gmtCreate":1637809697526,"gmtModify":1637809697589,"author":{"id":"3574933488250733","authorId":"3574933488250733","name":"DoubleClick","avatar":"https://static.tigerbbs.com/91c1a51c4f84aa921e0b29d4e1b8f7e1","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574933488250733","idStr":"3574933488250733"},"themes":[],"htmlText":"小米就是要放长线钓大鱼！<a href=\"https://laohu8.com/S/01810\">$XIAOMI-W(01810)$</a>","listText":"小米就是要放长线钓大鱼！<a href=\"https://laohu8.com/S/01810\">$XIAOMI-W(01810)$</a>","text":"小米就是要放长线钓大鱼！$XIAOMI-W(01810)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/874434632","repostId":"874394828","repostType":1,"repost":{"id":874394828,"gmtCreate":1637727980561,"gmtModify":1637730601856,"author":{"id":"3502767768442965","authorId":"3502767768442965","name":"话题虎","avatar":"https://static.tigerbbs.com/d418c2def5dc1d094b03270b450f71ce","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3502767768442965","idStr":"3502767768442965"},"themes":[],"title":"小米净利润大长25.4%！为什么又跌了？何时能抄底？","htmlText":" 昨天，小米发布Q3财报： 营收781亿元，同比增长8.2%；净利润52亿元，同比增长25.4%。 分业务来看： 智能手机： 三季度收入478亿元。 手机销售单价同比增长6.7%，达到1,090.5元，整体毛利率同比增长4.4个百分点，达到12.8%； 本季度智能手机出货量4,390万部，排名世界第三，前三季出货量与去年全年相当； 高端旗舰手机出货量近1800万台，占比超12%。 IoT与生活消费产品： 三季度收入209亿元，同比增长15.5%； 平板、智能电视、空调出货量持续增加； 在可穿戴产品，第三季度全球市场份额排名第二。 互联网服务业务： 三季度收入73亿元，同比增长27.1%，创历史新高； 毛利率73.6%，同比提升13.1个百分点； 广告收入48亿元，同比增长44.7%； 游戏收入10亿元，同比增长25.0%。 从地区上看，三季度： 境外收入，占比高达52.4%； 小米手机在全球11个国家和地区市占率排名第一，在全球59个国家和地区市占率排名前五；在印度市场连续第16个季度保持出货量第一。 智能电动汽车和其他业务： 团队成员已超过500人，预计2024年上半年正式量产； AIoT平台已连接的IoT设备（不包括智能手机、平板及笔记本计算机）数首次突破4&nbsp;亿，同比增长33.1%； 小米在中国大陆的零售店总数已突破10,000家。 小话感觉小米又交出了一份非常ok的财报，可是为啥股价大跌呢？ 想不通。 …… 最后，大家聊一聊： 你认为小米的财报ok吗？小米跌到什么时候能抄底？ 精彩留言用户可获得888社区积分噢！ <a target=\"_blank\" href=\"https://laohu8.com/S/01810\">$小米集团-W(01810)$</a>","listText":" 昨天，小米发布Q3财报： 营收781亿元，同比增长8.2%；净利润52亿元，同比增长25.4%。 分业务来看： 智能手机： 三季度收入478亿元。 手机销售单价同比增长6.7%，达到1,090.5元，整体毛利率同比增长4.4个百分点，达到12.8%； 本季度智能手机出货量4,390万部，排名世界第三，前三季出货量与去年全年相当； 高端旗舰手机出货量近1800万台，占比超12%。 IoT与生活消费产品： 三季度收入209亿元，同比增长15.5%； 平板、智能电视、空调出货量持续增加； 在可穿戴产品，第三季度全球市场份额排名第二。 互联网服务业务： 三季度收入73亿元，同比增长27.1%，创历史新高； 毛利率73.6%，同比提升13.1个百分点； 广告收入48亿元，同比增长44.7%； 游戏收入10亿元，同比增长25.0%。 从地区上看，三季度： 境外收入，占比高达52.4%； 小米手机在全球11个国家和地区市占率排名第一，在全球59个国家和地区市占率排名前五；在印度市场连续第16个季度保持出货量第一。 智能电动汽车和其他业务： 团队成员已超过500人，预计2024年上半年正式量产； AIoT平台已连接的IoT设备（不包括智能手机、平板及笔记本计算机）数首次突破4&nbsp;亿，同比增长33.1%； 小米在中国大陆的零售店总数已突破10,000家。 小话感觉小米又交出了一份非常ok的财报，可是为啥股价大跌呢？ 想不通。 …… 最后，大家聊一聊： 你认为小米的财报ok吗？小米跌到什么时候能抄底？ 精彩留言用户可获得888社区积分噢！ <a target=\"_blank\" href=\"https://laohu8.com/S/01810\">$小米集团-W(01810)$</a>","text":"昨天，小米发布Q3财报： 营收781亿元，同比增长8.2%；净利润52亿元，同比增长25.4%。 分业务来看： 智能手机： 三季度收入478亿元。 手机销售单价同比增长6.7%，达到1,090.5元，整体毛利率同比增长4.4个百分点，达到12.8%； 本季度智能手机出货量4,390万部，排名世界第三，前三季出货量与去年全年相当； 高端旗舰手机出货量近1800万台，占比超12%。 IoT与生活消费产品： 三季度收入209亿元，同比增长15.5%； 平板、智能电视、空调出货量持续增加； 在可穿戴产品，第三季度全球市场份额排名第二。 互联网服务业务： 三季度收入73亿元，同比增长27.1%，创历史新高； 毛利率73.6%，同比提升13.1个百分点； 广告收入48亿元，同比增长44.7%； 游戏收入10亿元，同比增长25.0%。 从地区上看，三季度： 境外收入，占比高达52.4%； 小米手机在全球11个国家和地区市占率排名第一，在全球59个国家和地区市占率排名前五；在印度市场连续第16个季度保持出货量第一。 智能电动汽车和其他业务： 团队成员已超过500人，预计2024年上半年正式量产； AIoT平台已连接的IoT设备（不包括智能手机、平板及笔记本计算机）数首次突破4 亿，同比增长33.1%； 小米在中国大陆的零售店总数已突破10,000家。 小话感觉小米又交出了一份非常ok的财报，可是为啥股价大跌呢？ 想不通。 …… 最后，大家聊一聊： 你认为小米的财报ok吗？小米跌到什么时候能抄底？ 精彩留言用户可获得888社区积分噢！ $小米集团-W(01810)$","images":[{"img":"https://static.tigerbbs.com/3f5a17d57ed7aba34cdfe013be4ef460","width":"1024","height":"640"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/874394828","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"subType":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1779,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":875615904,"gmtCreate":1637642120721,"gmtModify":1637642124644,"author":{"id":"3574933488250733","authorId":"3574933488250733","name":"DoubleClick","avatar":"https://static.tigerbbs.com/91c1a51c4f84aa921e0b29d4e1b8f7e1","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574933488250733","idStr":"3574933488250733"},"themes":[],"htmlText":"[Cool]&nbsp;","listText":"[Cool]&nbsp;","text":"[Cool]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875615904","repostId":"1107351089","repostType":4,"isVote":1,"tweetType":1,"viewCount":1686,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":874261442,"gmtCreate":1637793878586,"gmtModify":1637793878691,"author":{"id":"3574933488250733","authorId":"3574933488250733","name":"DoubleClick","avatar":"https://static.tigerbbs.com/91c1a51c4f84aa921e0b29d4e1b8f7e1","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574933488250733","idStr":"3574933488250733"},"themes":[],"htmlText":"我的计划是等着看","listText":"我的计划是等着看","text":"我的计划是等着看","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/874261442","repostId":"874922613","repostType":1,"repost":{"id":874922613,"gmtCreate":1637722036227,"gmtModify":1637723087352,"author":{"id":"3527667596890271","authorId":"3527667596890271","name":"Buy_Sell","avatar":"https://static.tigerbbs.com/a5f0ed79a338c758a22e0b4ea13bf9d2","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3527667596890271","idStr":"3527667596890271"},"themes":[],"title":"🚀【11月24日】涨跌不一，油价上演大逆转！今天什么值得买","htmlText":"聊聊今日份的交易想法，包括对于大盘走势后续的看法？看涨/看跌哪只股票、晒晒单等等。 港股市场 11月24日讯，港股三大指数开盘涨跌不一，恒指涨0.08%报24672点，国指跌0.02%报8825点，恒生科技指数跌0.1%报6317点。 盘面上，大型科技股多数延续跌势，<a target=\"_blank\" href=\"https://laohu8.com/S/09999\">$网易-S(09999)$</a> 跌2.44%，<a target=\"_blank\" href=\"https://laohu8.com/S/00700\">$腾讯控股(00700)$</a> 、<a target=\"_blank\" href=\"https://laohu8.com/S/09988\">$阿里巴巴-SW(09988)$</a> 、<a target=\"_blank\" href=\"https://laohu8.com/S/09618\">$京东集团-SW(09618)$</a> 均跌超1%，<a target=\"_blank\" href=\"https://laohu8.com/S/01024\">$快手-W(01024)$</a> 大涨4.5%；家电股、汽车股、半导体股、体育用品股、建材水泥股、燃气股普跌，内房股、保险股涨跌参半；国际油价上涨，石油股集体高开，<a target=\"_blank\" href=\"https://laohu8.com/S/00857\">$中国石油股份(00857)$</a> 涨超3%，恒大系继续走强，恒腾网络再涨3.58%。 <a target=\"_blank\" href=\"https://laohu8.com/S/01024\">$快手-W(01024)$</a> 绩后涨超4%，第三季度收入同比增33.4%，调整后净亏损48.22亿元。","listText":"聊聊今日份的交易想法，包括对于大盘走势后续的看法？看涨/看跌哪只股票、晒晒单等等。 港股市场 11月24日讯，港股三大指数开盘涨跌不一，恒指涨0.08%报24672点，国指跌0.02%报8825点，恒生科技指数跌0.1%报6317点。 盘面上，大型科技股多数延续跌势，<a target=\"_blank\" href=\"https://laohu8.com/S/09999\">$网易-S(09999)$</a> 跌2.44%，<a target=\"_blank\" href=\"https://laohu8.com/S/00700\">$腾讯控股(00700)$</a> 、<a target=\"_blank\" href=\"https://laohu8.com/S/09988\">$阿里巴巴-SW(09988)$</a> 、<a target=\"_blank\" href=\"https://laohu8.com/S/09618\">$京东集团-SW(09618)$</a> 均跌超1%，<a target=\"_blank\" href=\"https://laohu8.com/S/01024\">$快手-W(01024)$</a> 大涨4.5%；家电股、汽车股、半导体股、体育用品股、建材水泥股、燃气股普跌，内房股、保险股涨跌参半；国际油价上涨，石油股集体高开，<a target=\"_blank\" href=\"https://laohu8.com/S/00857\">$中国石油股份(00857)$</a> 涨超3%，恒大系继续走强，恒腾网络再涨3.58%。 <a target=\"_blank\" href=\"https://laohu8.com/S/01024\">$快手-W(01024)$</a> 绩后涨超4%，第三季度收入同比增33.4%，调整后净亏损48.22亿元。","text":"聊聊今日份的交易想法，包括对于大盘走势后续的看法？看涨/看跌哪只股票、晒晒单等等。 港股市场 11月24日讯，港股三大指数开盘涨跌不一，恒指涨0.08%报24672点，国指跌0.02%报8825点，恒生科技指数跌0.1%报6317点。 盘面上，大型科技股多数延续跌势，$网易-S(09999)$ 跌2.44%，$腾讯控股(00700)$ 、$阿里巴巴-SW(09988)$ 、$京东集团-SW(09618)$ 均跌超1%，$快手-W(01024)$ 大涨4.5%；家电股、汽车股、半导体股、体育用品股、建材水泥股、燃气股普跌，内房股、保险股涨跌参半；国际油价上涨，石油股集体高开，$中国石油股份(00857)$ 涨超3%，恒大系继续走强，恒腾网络再涨3.58%。 $快手-W(01024)$ 绩后涨超4%，第三季度收入同比增33.4%，调整后净亏损48.22亿元。","images":[{"img":"https://static.tigerbbs.com/8c224c9889536a14f83eca563ae0bb07","width":"666","height":"284"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/874922613","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"subType":2,"comments":[],"imageCount":2,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1766,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}